Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 41 of 827 for:    Advanced | Neuroendocrine Tumors

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01525550
Recruitment Status : Completed
First Posted : February 3, 2012
Results First Posted : May 19, 2017
Last Update Posted : March 5, 2019
Sponsor:
Information provided by (Responsible Party):
Pfizer

Study Type Interventional
Study Design Masking: None (Open Label);   Primary Purpose: Other
Condition Well-differentiated Pancreatic Neuroendocrine Tumor
Intervention Drug: sunitinib
Enrollment 106
Recruitment Details  
Pre-assignment Details  
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants. Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Period Title: Overall Study
Started 61 45
Completed 0 0
Not Completed 61 45
Reason Not Completed
Withdrawal by Subject             2             0
Lost to Follow-up             4             1
Death             10             19
Other Unspecified             0             2
Ongoing             45             23
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort Total
Hide Arm/Group Description Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants. Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy). Total of all reporting groups
Overall Number of Baseline Participants 61 45 106
Hide Baseline Analysis Population Description
Full analysis set (FAS) included all participants who were enrolled into the study regardless of whether participants received study drug or not.
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 61 participants 45 participants 106 participants
55.4  (8.9) 53.5  (9.1) 54.6  (9.0)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 61 participants 45 participants 106 participants
Female
31
  50.8%
12
  26.7%
43
  40.6%
Male
30
  49.2%
33
  73.3%
63
  59.4%
1.Primary Outcome
Title Progression-Free Survival (PFS): Investigator Assessment
Hide Description Investigator assessed PFS was defined as the time (in months) from the date of enrollment in study to the date of first documented objective tumor progression or death (due to any cause), whichever occurs first. PFS calculated as (first event date minus date of enrollment plus 1)/30.4. If progression or death was not observed, the participant was censored at the date of the participant’s last progression-free tumor assessment prior to the study cut-off date. Progression as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria was defined as: greater than or equal to (>=) 20 percent increase in sum of longest diameter (LD) of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. The analysis was performed by Kaplan-Meier method.
Time Frame Baseline until disease progression or death due to any cause (up to 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 61 45
Median (95% Confidence Interval)
Unit of Measure: months
13.2
(7.4 to 16.8)
13.0
(9.2 to 20.4)
2.Secondary Outcome
Title Progression-Free Survival (PFS): Independent Radiological Review (IRR) Assessment
Hide Description IRR assessed PFS was defined as the time (in months) from the date of enrollment in study until the date of first documented objective tumor progression or death (due to any cause), whichever occurs first. PFS calculated as (first event date minus date of enrollment plus 1)/30.4. If progression or death was not observed, the participant was censored at the date of the participant’s last progression-free tumor assessment prior to the study cut-off date. Progression as per RECIST 1.0 criteria was defined as: >=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. The analysis was performed by Kaplan-Meier method.
Time Frame Baseline until disease progression or death due to any cause (up to 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 61 45
Median (95% Confidence Interval)
Unit of Measure: months
11.1
(5.5 to 16.7)
9.5
(7.4 to 18.4)
3.Secondary Outcome
Title Time to Tumor Progression (TTP): Investigator Assessment
Hide Description Investigator assessed TTP was defined as the time (in months) from the date of enrollment in study until the date of first documentation of objective tumor progression. TTP calculated as (first event date minus date of enrollment plus 1)/30.4. Progression as per RECIST 1.0 was defined as >=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. The analysis was performed by Kaplan-Meier method.
Time Frame Baseline until first documented tumor progression (up to 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 61 45
Median (95% Confidence Interval)
Unit of Measure: months
14.8
(7.5 to 16.8)
14.5
(9.2 to 20.4)
4.Secondary Outcome
Title Overall Survival (OS)
Hide Description OS was defined as the time (in months) from date of enrollment in study to the date of death due to any cause. If death was not observed, the participant was censored at the earliest of the last date the participant was known to be alive or the study cut-off date. The analysis was performed by Kaplan-Meier method.
Time Frame Baseline until death or study cut-off (up to 5 years)
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 61 45
Median (95% Confidence Interval)
Unit of Measure: months
NA [1] 
(28.9 to NA)
33.8 [2] 
(20.3 to NA)
[1]
Median and upper limit of 95% CI was not estimable due to the low number of participants who died.
[2]
Upper limit of 95% CI was not estimable due to the low number of participants who died.
5.Secondary Outcome
Title Percentage of Participants With Objective Response (OR): Investigator Assessment
Hide Description Investigator assessed OR in participants was defined as having a complete response (CR) or partial response (PR) according to RECIST 1.0 and sustained for at least 4 weeks. CR was defined as disappearance of all target and non-target lesions. PR was defined as >=30 percent decrease in the sum of the LD of the target lesions taking as a reference the baseline sum LD. Percentage of participants with investigator assessed OR were reported.
Time Frame Baseline until disease progression or death due to any cause (up to 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 61 45
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
21.3
(11.9 to 33.7)
28.9
(16.4 to 44.3)
6.Secondary Outcome
Title Duration of Response (DOR): Investigator Assessment
Hide Description Investigator assessed DOR was defined as the time (in months) from the date of first documented objective tumor response (CR or PR), that was subsequently confirmed, to the first documented objective tumor progression or death due to any cause, whichever occurred first. According to RECIST 1.0, CR was defined as disappearance of all target and non-target lesions. PR was defined as >=30 percent decrease in the sum of the LD of the target lesions taking as a reference the baseline sum LD. Progression as per RECIST version 1.0 was defined as >=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.
Time Frame Baseline until disease progression or death due to any cause (up to 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis was performed on only those participants who had objective response as per investigator assessment.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 13 13
Median (95% Confidence Interval)
Unit of Measure: months
19.1 [1] 
(10.1 to NA)
14.7
(5.5 to 21.9)
[1]
Upper limit of 95% CI was not estimable due to the low number of participants with events.
7.Secondary Outcome
Title Time to Tumor Response (TTR): Investigator Assessment
Hide Description Investigator assessed TTR was defined as the time (in months) from date of enrollment in study until date of first documentation of objective tumor response (CR or PR) that was subsequently confirmed. TTR was calculated as (first response date minus the date of enrollment plus 1) divided by 30.4. As per RECIST 1.0, CR was defined as disappearance of all target and non-target lesions and PR was defined as >=30 percent decrease in the sum of the LD of the target lesions taking as a reference the baseline sum LD.
Time Frame Baseline until first documented objective tumor response (up to 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis was performed on only those participants who had objective response as per investigator assessment.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 13 13
Median (Full Range)
Unit of Measure: months
3.8
(1.0 to 11.1)
3.8
(1.0 to 9.3)
8.Secondary Outcome
Title Percentage of Participants With Objective Response (OR): Independent Radiological Review (IRR) Assessment
Hide Description IRR assessed OR in participants was defined as having a CR or PR according to Choi criteria and sustained for at least 4 weeks. According to Choi criteria, CR was defined as disappearance of all target and non-target lesions and no new lesions. PR was defined as a decrease of >=10 percent in tumor size or a decrease in tumor density (HU) of 15 percent or more on Computed tomography (CT) with no new lesions and no obvious progression of non-measurable disease. Percentage of participants with objective response were reported in this outcome measure.
Time Frame Baseline until disease progression or death due to any cause (up to 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 61 45
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
52.5
(39.3 to 65.4)
55.6
(40.0 to 70.4)
9.Secondary Outcome
Title Duration of Response (DOR): Independent Radiological Review (IRR) Assessment
Hide Description IRR assessed DOR was defined as the time (in months) from the date of first documented objective tumor response (CR or PR) that was subsequently confirmed to the first documented objective tumor progression or death due to any cause, whichever occurred first. According to Choi criteria, CR was defined as disappearance of all target and non-target lesions and no new lesions. PR was defined as a decrease of >=10 percent in tumor size or a decrease in tumor density (HU) of 15 percent or more on CT with no new lesions and no obvious progression of non-measurable disease.
Time Frame Baseline until disease progression or death due to any cause (up to 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis was performed on only those participants who had objective response as per IRR assessment.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 32 25
Median (95% Confidence Interval)
Unit of Measure: months
NA [1] 
(17.8 to NA)
19.2
(15.7 to 35.9)
[1]
Median and 95% CI was not estimable due to the small number of participants who encountered tumor progression or death.
10.Secondary Outcome
Title Time to Tumor Response (TTR): Independent Radiological Review (IRR) Assessment
Hide Description IRR assessed TTR was defined as the time (in months) from date of enrollment in study until first documentation of objective tumor response (CR or PR) that was subsequently confirmed. TTR was calculated as (first response date minus the date of enrollment plus 1) divided by 30.4. According to Choi criteria, CR was defined as disappearance of all target and non-target lesions and no new lesions. PR was defined as a decrease of >=10 percent in tumor size or a decrease in tumor density (HU) of 15 percent or more on CT with no new lesions and no obvious progression of non-measurable disease.
Time Frame Baseline until first documented objective tumor response (up to 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis was performed on only those participants who had objective response as per IRR assessment.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 32 25
Median (Full Range)
Unit of Measure: months
1.0
(0.8 to 7.3)
1.0
(0.9 to 3.7)
11.Secondary Outcome
Title Percentage of Participants With Chromogranin A (CgA) Response
Hide Description CgA response in participants was defined as having confirmed CgA CR or CgA PR, relative to the population with an elevated baseline CgA value in the blood. CgA CR was defined as decrease from a high baseline value of CgA in the blood to one that fell within the normal range. CgA PR was defined as a decrease of greater than or equal to 50 percent from a high baseline value of CgA. Normal baseline value of CgA in blood was 39.0 ng/mL. Confirmed responses were those that persisted for at least 4 weeks after initial documentation of response. Blood levels of CgA were assessed and percentage of participants with CgA response were reported.
Time Frame Baseline until CgA response or death due to any cause (up to 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 61 45
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
16.4
(9.6 to 32.5)
11.1
(4.0 to 25.6)
12.Secondary Outcome
Title Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
Hide Description EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to assess the participant quality of life. First 28 questions used for evaluating 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, pain) and other single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Each question was assessed on 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much); high score represented high level of symptomatology/problem. Last 2 questions used for evaluating global health status (GHS)/quality of life. Each question was assessed on 7-point scale (1=very poor to 7=excellent). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning.
Time Frame Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, End of treatment (up to maximum duration of 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not. Here, “0 participants” in the “number analyzed” field signifies none of the participants were evaluable in the given group at this time point, hence data was not reported.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 61 45
Mean (Standard Deviation)
Unit of Measure: units on a scale
Global health status:Cycle 1 Number Analyzed 61 participants 43 participants
71.31  (21.111) 66.09  (20.282)
Global health status: Cycle 2 Number Analyzed 56 participants 41 participants
69.94  (19.311) 65.45  (20.880)
Global health status: Cycle 3 Number Analyzed 55 participants 40 participants
70.30  (21.502) 60.83  (26.768)
Global health status: Cycle 4 Number Analyzed 50 participants 38 participants
70.00  (21.429) 61.84  (25.010)
Global health status: Cycle 5 Number Analyzed 47 participants 34 participants
69.15  (19.421) 65.93  (24.306)
Global health status: Cycle 6 Number Analyzed 43 participants 31 participants
68.41  (18.053) 65.32  (20.310)
Global health status: Cycle 7 Number Analyzed 39 participants 29 participants
68.38  (21.132) 61.21  (24.016)
Global health status: Cycle 8 Number Analyzed 37 participants 25 participants
70.05  (17.062) 65.33  (20.649)
Global health status: Cycle 9 Number Analyzed 35 participants 26 participants
66.90  (20.058) 65.71  (20.045)
Global health status: Cycle 10 Number Analyzed 35 participants 23 participants
68.10  (20.561) 63.04  (18.434)
Global health status: Cycle 11 Number Analyzed 35 participants 24 participants
63.81  (21.384) 66.67  (19.812)
Global health status: Cycle 12 Number Analyzed 35 participants 22 participants
65.71  (22.395) 64.77  (22.848)
Global health status: Cycle 13 Number Analyzed 34 participants 21 participants
67.89  (20.733) 66.67  (19.365)
Global health status: Cycle 14 Number Analyzed 31 participants 19 participants
68.28  (20.797) 57.89  (18.937)
Global health status: Cycle 15 Number Analyzed 30 participants 17 participants
66.67  (22.318) 64.71  (21.757)
Global health status: Cycle 16 Number Analyzed 27 participants 16 participants
64.51  (21.005) 67.19  (17.339)
Global health status: Cycle 17 Number Analyzed 22 participants 15 participants
62.50  (23.110) 67.78  (15.706)
Global health status: Cycle 18 Number Analyzed 17 participants 14 participants
58.33  (24.826) 70.83  (18.125)
Global health status: Cycle 19 Number Analyzed 12 participants 14 participants
54.86  (24.736) 66.67  (20.672)
Global health status: Cycle 20 Number Analyzed 11 participants 13 participants
55.30  (25.893) 64.74  (17.398)
Global health status: Cycle 21 Number Analyzed 11 participants 12 participants
55.30  (23.650) 65.28  (18.407)
Global health status: Cycle 22 Number Analyzed 11 participants 11 participants
56.06  (23.889) 62.88  (27.224)
Global health status: Cycle 23 Number Analyzed 11 participants 10 participants
56.82  (24.386) 59.17  (20.953)
Global health status: Cycle 24 Number Analyzed 10 participants 10 participants
50.00  (23.570) 60.83  (19.265)
Global health status: Cycle 25 Number Analyzed 10 participants 8 participants
51.67  (19.954) 61.46  (16.022)
Global health status: Cycle 26 Number Analyzed 7 participants 7 participants
50.00  (20.972) 65.48  (13.968)
Global health status: Cycle 27 Number Analyzed 6 participants 8 participants
41.67  (12.910) 61.46  (17.216)
Global health status: Cycle 28 Number Analyzed 7 participants 8 participants
44.05  (20.813) 61.46  (16.022)
Global health status: Cycle 29 Number Analyzed 5 participants 7 participants
56.67  (19.003) 63.10  (16.567)
Global health status: Cycle 30 Number Analyzed 4 participants 7 participants
52.08  (21.916) 64.29  (14.996)
Global health status: Cycle 31 Number Analyzed 2 participants 7 participants
58.33  (11.785) 60.71  (20.813)
Global health status: Cycle 32 Number Analyzed 3 participants 6 participants
61.11  (19.245) 59.72  (15.290)
Global health status: Cycle 33 Number Analyzed 3 participants 6 participants
61.11  (12.729) 55.56  (22.771)
Global health status: Cycle 34 Number Analyzed 3 participants 6 participants
58.33  (25.000) 55.56  (20.861)
Global health status: Cycle 35 Number Analyzed 2 participants 6 participants
66.67  (23.570) 61.11  (13.608)
Global health status: Cycle 36 Number Analyzed 1 participants 5 participants
83.33 [1]   (NA) 58.33  (16.667)
Global health status: Cycle 37 Number Analyzed 1 participants 4 participants
83.33 [1]   (NA) 58.33  (21.517)
Global health status: Cycle 38 Number Analyzed 0 participants 4 participants
58.33  (21.517)
Global health status: Cycle 39 Number Analyzed 1 participants 3 participants
83.33 [1]   (NA) 50.00  (16.667)
Global health status: Cycle 40 Number Analyzed 1 participants 3 participants
83.33 [1]   (NA) 50.00  (16.667)
Global health status: Cycle 41 Number Analyzed 0 participants 3 participants
50.00  (16.667)
Global health status: Cycle 42 Number Analyzed 0 participants 2 participants
45.83  (5.893)
Global health status: Cycle 43 Number Analyzed 0 participants 1 participants
50.00 [1]   (NA)
Global health status: EOT Number Analyzed 33 participants 30 participants
60.10  (22.318) 50.00  (22.210)
Physical Functioning: Cycle 1 Number Analyzed 61 participants 44 participants
90.38  (14.733) 86.93  (12.677)
Physical Functioning: Cycle 2 Number Analyzed 57 participants 42 participants
89.71  (10.988) 86.51  (13.929)
Physical Functioning: Cycle 3 Number Analyzed 55 participants 40 participants
88.73  (12.886) 85.00  (17.263)
Physical Functioning: Cycle 4 Number Analyzed 50 participants 38 participants
89.07  (10.412) 83.68  (16.958)
Physical Functioning: Cycle 5 Number Analyzed 47 participants 34 participants
88.23  (11.311) 87.06  (17.519)
Physical Functioning: Cycle 6 Number Analyzed 43 participants 31 participants
87.91  (11.293) 83.44  (18.924)
Physical Functioning: Cycle 7 Number Analyzed 39 participants 29 participants
86.24  (12.891) 84.14  (15.473)
Physical Functioning: Cycle 8 Number Analyzed 37 participants 25 participants
85.23  (12.486) 88.27  (11.102)
Physical Functioning: Cycle 9 Number Analyzed 35 participants 26 participants
84.00  (13.255) 87.18  (14.474)
Physical Functioning: Cycle 10 Number Analyzed 35 participants 23 participants
86.67  (11.771) 87.25  (15.943)
Physical Functioning: Cycle 11 Number Analyzed 35 participants 24 participants
84.19  (12.944) 90.83  (10.552)
Physical Functioning: Cycle 12 Number Analyzed 35 participants 22 participants
84.38  (15.419) 88.48  (11.489)
Physical Functioning: Cycle 13 Number Analyzed 34 participants 21 participants
87.45  (11.808) 89.52  (10.016)
Physical Functioning: Cycle 14 Number Analyzed 31 participants 19 participants
86.67  (12.996) 86.67  (10.423)
Physical Functioning: Cycle 15 Number Analyzed 30 participants 17 participants
85.33  (11.534) 89.02  (11.041)
Physical Functioning: Cycle 16 Number Analyzed 27 participants 16 participants
83.70  (18.053) 89.58  (10.319)
Physical Functioning: Cycle 17 Number Analyzed 22 participants 15 participants
82.42  (16.657) 88.00  (9.155)
Physical Functioning: Cycle 18 Number Analyzed 17 participants 14 participants
82.35  (18.248) 90.95  (8.516)
Physical Functioning: Cycle 19 Number Analyzed 12 participants 14 participants
75.00  (22.406) 89.52  (9.324)
Physical Functioning: Cycle 20 Number Analyzed 11 participants 13 participants
74.55  (20.181) 89.74  (8.439)
Physical Functioning: Cycle 21 Number Analyzed 11 participants 12 participants
75.15  (17.911) 90.00  (7.785)
Physical Functioning: Cycle 22 Number Analyzed 11 participants 11 participants
77.58  (22.563) 81.82  (24.782)
Physical Functioning: Cycle 23 Number Analyzed 11 participants 10 participants
77.73  (18.170) 82.67  (14.470)
Physical Functioning: Cycle 24 Number Analyzed 10 participants 10 participants
72.67  (22.760) 82.67  (14.807)
Physical Functioning: Cycle 25 Number Analyzed 10 participants 8 participants
74.67  (23.685) 89.17  (10.653)
Physical Functioning: Cycle 26 Number Analyzed 7 participants 7 participants
66.67  (25.531) 83.81  (13.801)
Physical Functioning: Cycle 27) Number Analyzed 6 participants 8 participants
62.22  (27.217) 85.83  (12.051)
Physical Functioning: Cycle 28 Number Analyzed 7 participants 8 participants
69.52  (21.381) 87.50  (11.513)
Physical Functioning: Cycle 29 Number Analyzed 6 participants 7 participants
80.00  (10.328) 83.81  (15.803)
Physical Functioning: Cycle 30 Number Analyzed 5 participants 7 participants
84.00  (3.651) 84.76  (11.362)
Physical Functioning: Cycle 31 Number Analyzed 3 participants 7 participants
77.78  (10.184) 85.71  (13.569)
Physical Functioning: Cycle 32 Number Analyzed 3 participants 6 participants
84.44  (3.849) 82.22  (10.037)
Physical Functioning: Cycle 33 Number Analyzed 3 participants 6 participants
73.33  (6.667) 83.33  (10.954)
Physical Functioning: Cycle 34 Number Analyzed 3 participants 6 participants
64.44  (21.430) 80.00  (12.649)
Physical Functioning: Cycle 35 Number Analyzed 2 participants 6 participants
70.00  (23.570) 78.89  (12.939)
Physical Functioning: Cycle 36 Number Analyzed 1 participants 5 participants
86.67 [1]   (NA) 80.00  (9.428)
Physical Functioning: Cycle 37 Number Analyzed 1 participants 4 participants
86.67 [1]   (NA) 76.67  (3.849)
Physical Functioning: Cycle 38 Number Analyzed 0 participants 4 participants
75.00  (6.383)
Physical Functioning: Cycle 39 Number Analyzed 1 participants 3 participants
86.67 [1]   (NA) 77.78  (3.849)
Physical Functioning: Cycle 40 Number Analyzed 1 participants 3 participants
93.33 [1]   (NA) 71.11  (10.184)
Physical Functioning: Cycle 41 Number Analyzed 0 participants 3 participants
77.78  (10.184)
Physical Functioning: Cycle 42 Number Analyzed 0 participants 2 participants
80.00  (0.000)
Physical Functioning: Cycle 43 Number Analyzed 0 participants 1 participants
80.00 [1]   (NA)
Physical Functioning: EOT Number Analyzed 33 participants 30 participants
76.16  (23.454) 78.00  (19.191)
Role Functioning: Cycle 1 Number Analyzed 60 participants 44 participants
88.33  (20.424) 85.61  (18.880)
Role Functioning: Cycle 2 Number Analyzed 57 participants 42 participants
85.67  (17.089) 80.56  (25.214)
Role Functioning: Cycle 3 Number Analyzed 55 participants 40 participants
85.15  (18.613) 80.83  (25.473)
Role Functioning: Cycle 4 Number Analyzed 50 participants 38 participants
84.67  (17.444) 80.26  (23.841)
Role Functioning: Cycle 5 Number Analyzed 47 participants 34 participants
85.82  (19.343) 82.35  (23.904)
Role Functioning: Cycle 6 Number Analyzed 43 participants 31 participants
86.05  (16.639) 79.57  (25.353)
Role Functioning: Cycle 7 Number Analyzed 39 participants 29 participants
83.33  (21.965) 81.03  (24.285)
Role Functioning: Cycle 8 Number Analyzed 37 participants 25 participants
80.63  (19.049) 85.33  (16.887)
Role Functioning: Cycle 9 Number Analyzed 35 participants 26 participants
76.19  (22.968) 80.77  (22.945)
Role Functioning: Cycle 10 Number Analyzed 35 participants 23 participants
82.86  (18.737) 83.33  (23.028)
Role Functioning: Cycle 11 Number Analyzed 35 participants 24 participants
79.52  (22.537) 86.11  (18.822)
Role Functioning: Cycle 12 Number Analyzed 35 participants 22 participants
79.52  (20.246) 84.85  (19.182)
Role Functioning: Cycle 13 Number Analyzed 34 participants 21 participants
82.35  (19.219) 84.13  (17.059)
Role Functioning: Cycle 14 Number Analyzed 31 participants 19 participants
81.72  (20.346) 79.82  (19.704)
Role Functioning: Cycle 15 Number Analyzed 30 participants 17 participants
77.22  (22.946) 77.45  (22.777)
Role Functioning: Cycle 16 Number Analyzed 27 participants 16 participants
77.16  (24.956) 84.38  (15.478)
Role Functioning: Cycle 17 Number Analyzed 22 participants 15 participants
74.24  (24.520) 82.22  (17.213)
Role Functioning: Cycle 18 Number Analyzed 17 participants 14 participants
75.49  (28.332) 84.52  (16.621)
Role Functioning: Cycle 19 Number Analyzed 12 participants 14 participants
66.67  (26.591) 79.76  (20.856)
Role Functioning: Cycle 20 Number Analyzed 11 participants 13 participants
69.70  (27.707) 80.77  (19.059)
Role Functioning: Cycle 21 Number Analyzed 11 participants 12 participants
68.18  (27.340) 79.17  (23.704)
Role Functioning: Cycle 22 Number Analyzed 11 participants 11 participants
68.18  (29.302) 71.21  (29.899)
Role Functioning: Cycle 23 Number Analyzed 11 participants 10 participants
63.64  (30.567) 71.67  (24.907)
Role Functioning: Cycle 24 Number Analyzed 10 participants 10 participants
60.00  (27.442) 76.67  (22.498)
Role Functioning: Cycle 25 Number Analyzed 10 participants 8 participants
58.33  (30.682) 77.08  (23.465)
Role Functioning: Cycle 26 Number Analyzed 7 participants 7 participants
57.14  (30.211) 83.33  (16.667)
Role Functioning: Cycle 27 Number Analyzed 6 participants 8 participants
58.33  (36.132) 77.08  (23.465)
Role Functioning: Cycle 28 Number Analyzed 7 participants 8 participants
59.52  (18.898) 79.17  (24.801)
Role Functioning: Cycle 29 Number Analyzed 6 participants 7 participants
75.00  (13.944) 78.57  (24.934)
Role Functioning: Cycle 30 Number Analyzed 5 participants 7 participants
90.00  (14.907) 76.19  (25.198)
Role Functioning: Cycle 31 Number Analyzed 3 participants 7 participants
83.33  (16.667) 78.57  (24.934)
Role Functioning: Cycle 32 Number Analyzed 3 participants 6 participants
94.44  (9.623) 77.78  (20.184)
Role Functioning: Cycle 33 Number Analyzed 3 participants 6 participants
88.89  (19.245) 72.22  (25.092)
Role Functioning: Cycle 34 Number Analyzed 3 participants 6 participants
72.22  (34.694) 69.44  (30.581)
Role Functioning: Cycle 35 Number Analyzed 2 participants 6 participants
75.00  (35.355) 72.22  (25.092)
Role Functioning: Cycle 36 Number Analyzed 1 participants 5 participants
100.00 [1]   (NA) 73.33  (19.003)
Role Functioning: Cycle 37 Number Analyzed 1 participants 4 participants
66.67 [1]   (NA) 70.83  (28.464)
Role Functioning: Cycle 38 Number Analyzed 0 participants 4 participants
66.67  (27.217)
Role Functioning: Cycle 39 Number Analyzed 1 participants 3 participants
100.00 [1]   (NA) 55.56  (19.245)
Role Functioning: Cycle 40 Number Analyzed 1 participants 3 participants
100.00 [1]   (NA) 55.56  (9.623)
Role Functioning: Cycle 41 Number Analyzed 0 participants 3 participants
55.56  (19.245)
Role Functioning: Cycle 42 Number Analyzed 0 participants 2 participants
66.67  (0.000)
Role Functioning: Cycle 43 Number Analyzed 0 participants 1 participants
66.67 [1]   (NA)
Role Functioning: EOT Number Analyzed 33 participants 30 participants
70.71  (26.031) 65.56  (36.075)
Emotional Functioning: Cycle 1 Number Analyzed 61 participants 43 participants
80.19  (18.644) 76.23  (18.238)
Emotional Functioning: Cycle 2 Number Analyzed 57 participants 41 participants
84.31  (17.619) 77.64  (17.021)
Emotional Functioning: Cycle 3 Number Analyzed 55 participants 40 participants
82.53  (18.792) 73.96  (24.401)
Emotional Functioning: Cycle 4 Number Analyzed 50 participants 38 participants
82.67  (16.906) 77.41  (22.167)
Emotional Functioning: Cycle 5 Number Analyzed 47 participants 34 participants
82.09  (18.632) 79.66  (21.141)
Emotional Functioning: Cycle 6 Number Analyzed 43 participants 31 participants
82.17  (17.871) 73.92  (24.696)
Emotional Functioning: Cycle 7 Number Analyzed 39 participants 29 participants
80.56  (21.059) 73.56  (26.075)
Emotional Functioning: Cycle 8 Number Analyzed 37 participants 25 participants
80.63  (21.877) 76.00  (18.991)
Emotional Functioning: Cycle 9 Number Analyzed 35 participants 26 participants
80.24  (19.812) 76.92  (18.304)
Emotional Functioning: Cycle 10 Number Analyzed 35 participants 23 participants
81.27  (19.818) 76.45  (21.998)
Emotional Functioning: Cycle 11 Number Analyzed 35 participants 24 participants
79.76  (19.311) 75.46  (20.587)
Emotional Functioning: Cycle 12 Number Analyzed 35 participants 22 participants
78.10  (23.052) 75.76  (22.700)
Emotional Functioning: Cycle 13 Number Analyzed 34 participants 21 participants
77.45  (22.429) 77.38  (19.211)
Emotional Functioning: Cycle 14 Number Analyzed 31 participants 19 participants
78.49  (20.387) 75.00  (24.375)
Emotional Functioning: Cycle 15 Number Analyzed 30 participants 17 participants
80.00  (21.173) 74.51  (23.839)
Emotional Functioning: Cycle 16 Number Analyzed 27 participants 16 participants
82.10  (22.133) 75.00  (24.343)
Emotional Functioning: Cycle 17 Number Analyzed 22 participants 15 participants
79.92  (23.522) 79.44  (19.382)
Emotional Functioning: Cycle 18 Number Analyzed 17 participants 14 participants
78.92  (23.592) 76.19  (25.499)
Emotional Functioning: Cycle 19 Number Analyzed 12 participants 14 participants
73.61  (28.611) 73.81  (25.288)
Emotional Functioning: Cycle 20 Number Analyzed 11 participants 13 participants
71.21  (29.666) 78.85  (25.823)
Emotional Functioning: Cycle 21 Number Analyzed 11 participants 12 participants
76.52  (28.824) 75.00  (25.624)
Emotional Functioning: Cycle 22 Number Analyzed 11 participants 11 participants
75.76  (30.834) 78.03  (22.445)
Emotional Functioning: Cycle 23 Number Analyzed 11 participants 10 participants
74.24  (30.834) 75.00  (27.778)
Emotional Functioning: Cycle 24 Number Analyzed 10 participants 10 participants
71.67  (28.921) 76.67  (22.153)
Emotional Functioning: Cycle 25 Number Analyzed 10 participants 8 participants
65.83  (33.206) 66.67  (29.881)
Emotional Functioning: Cycle 26 Number Analyzed 7 participants 7 participants
71.43  (34.979) 77.38  (17.156)
Emotional Functioning: Cycle 27 Number Analyzed 6 participants 8 participants
56.94  (32.667) 68.75  (29.124)
Emotional Functioning: Cycle 28 Number Analyzed 7 participants 8 participants
65.48  (34.166) 68.75  (29.463)
Emotional Functioning: Cycle 29 Number Analyzed 5 participants 7 participants
68.33  (29.698) 71.43  (31.127)
Emotional Functioning: Cycle 30 Number Analyzed 4 participants 7 participants
72.92  (29.950) 70.24  (31.497)
Emotional Functioning: Cycle 31 Number Analyzed 2 participants 7 participants
45.83  (17.678) 72.62  (26.227)
Emotional Functioning: Cycle 32 Number Analyzed 3 participants 6 participants
69.44  (29.266) 69.44  (33.610)
Emotional Functioning: Cycle 33 Number Analyzed 3 participants 6 participants
77.78  (19.245) 70.83  (27.764)
Emotional Functioning: Cycle 34 Number Analyzed 3 participants 6 participants
66.67  (33.333) 66.67  (34.561)
Emotional Functioning: Cycle 35 Number Analyzed 2 participants 6 participants
83.33  (23.570) 68.06  (33.918)
Emotional Functioning: Cycle 36 Number Analyzed 1 participants 5 participants
100.00 [1]   (NA) 71.67  (31.513)
Emotional Functioning: Cycle 37 Number Analyzed 1 participants 4 participants
100.00 [1]   (NA) 77.08  (35.600)
Emotional Functioning: Cycle 38 Number Analyzed 0 participants 4 participants
70.83  (42.219)
Emotional Functioning: Cycle 39 Number Analyzed 1 participants 3 participants
100.00 [1]   (NA) 63.89  (48.829)
Emotional Functioning: Cycle 40 Number Analyzed 1 participants 3 participants
100.00 [1]   (NA) 66.67  (38.188)
Emotional Functioning: Cycle 41 Number Analyzed 0 participants 3 participants
58.33  (41.667)
Emotional Functioning: Cycle 42 Number Analyzed 0 participants 2 participants
54.17  (64.818)
Emotional Functioning: Cycle 43 Number Analyzed 0 participants 1 participants
100.00 [1]   (NA)
Emotional Functioning: EOT Number Analyzed 33 participants 30 participants
67.17  (23.748) 66.94  (27.024)
Cognitive Functioning: Cycle 1 Number Analyzed 61 participants 43 participants
90.16  (15.329) 88.76  (15.310)
Cognitive Functioning: Cycle 2 Number Analyzed 57 participants 41 participants
88.89  (15.537) 89.43  (13.310)
Cognitive Functioning: Cycle 3 Number Analyzed 55 participants 40 participants
89.09  (15.119) 87.50  (19.882)
Cognitive Functioning: Cycle 4 Number Analyzed 50 participants 38 participants
89.67  (12.993) 87.72  (15.346)
Cognitive Functioning: Cycle 5 Number Analyzed 47 participants 34 participants
88.65  (15.583) 85.29  (22.385)
Cognitive Functioning: Cycle 6 Number Analyzed 43 participants 31 participants
89.53  (15.006) 82.80  (25.993)
Cognitive Functioning: Cycle 7 Number Analyzed 39 participants 29 participants
89.74  (14.618) 85.06  (20.091)
Cognitive Functioning: Cycle 8 Number Analyzed 37 participants 25 participants
87.39  (13.836) 83.33  (21.517)
Cognitive Functioning: Cycle 9 Number Analyzed 35 participants 26 participants
88.10  (16.455) 85.26  (20.181)
Cognitive Functioning: Cycle 10 Number Analyzed 35 participants 23 participants
88.10  (13.750) 83.33  (21.320)
Cognitive Functioning: Cycle 11 Number Analyzed 35 participants 24 participants
86.67  (16.068) 86.11  (17.492)
Cognitive Functioning: Cycle 12 Number Analyzed 35 participants 22 participants
86.67  (13.886) 86.36  (18.993)
Cognitive Functioning: Cycle 13 Number Analyzed 34 participants 21 participants
87.25  (15.922) 85.71  (19.211)
Cognitive Functioning: Cycle 14 Number Analyzed 31 participants 19 participants
88.71  (13.185) 77.19  (22.368)
Cognitive Functioning: Cycle 15 Number Analyzed 30 participants 17 participants
88.33  (12.495) 80.39  (27.154)
Cognitive Functioning: Cycle 16 Number Analyzed 27 participants 16 participants
88.27  (12.067) 80.21  (24.509)
Cognitive Functioning: Cycle 17 Number Analyzed 22 participants 15 participants
89.39  (12.112) 84.44  (20.380)
Cognitive Functioning: Cycle 18 Number Analyzed 17 participants 14 participants
88.24  (14.148) 79.76  (24.615)
Cognitive Functioning: Cycle 19 Number Analyzed 12 participants 14 participants
88.89  (12.975) 78.57  (24.832)
Cognitive Functioning: Cycle 20 Number Analyzed 11 participants 13 participants
90.91  (11.459) 82.05  (24.964)
Cognitive Functioning: Cycle 21 Number Analyzed 11 participants 12 participants
89.39  (11.237) 76.39  (26.071)
Cognitive Functioning: Cycle 22 Number Analyzed 11 participants 11 participants
86.36  (12.513) 81.82  (20.350)
Cognitive Functioning: Cycle 23 Number Analyzed 11 participants 10 participants
84.85  (11.677) 76.67  (27.442)
Cognitive Functioning: Cycle 24 Number Analyzed 10 participants 10 participants
85.00  (16.574) 81.67  (19.954)
Cognitive Functioning: Cycle 25 Number Analyzed 10 participants 8 participants
81.67  (18.342) 75.00  (25.198)
Cognitive Functioning: Cycle 26 Number Analyzed 7 participants 7 participants
85.71  (20.250) 85.71  (17.817)
Cognitive Functioning: Cycle 27 Number Analyzed 6 participants 8 participants
75.00  (20.412) 77.08  (25.099)
Cognitive Functioning: Cycle 28 Number Analyzed 7 participants 8 participants
76.19  (18.898) 72.92  (29.463)
Cognitive Functioning: Cycle 29 Number Analyzed 5 participants 7 participants
76.67  (14.907) 78.57  (26.726)
Cognitive Functioning: Cycle 30 Number Analyzed 4 participants 7 participants
75.00  (16.667) 76.19  (31.706)
Cognitive Functioning: Cycle 31 Number Analyzed 2 participants 7 participants
83.33  (23.570) 73.81  (31.706)
Cognitive Functioning: Cycle 32 Number Analyzed 3 participants 6 participants
83.33  (16.667) 69.44  (32.347)
Cognitive Functioning: Cycle 33 Number Analyzed 3 participants 6 participants
88.89  (19.245) 69.44  (26.701)
Cognitive Functioning: Cycle 34 Number Analyzed 3 participants 6 participants
77.78  (9.623) 66.67  (34.960)
Cognitive Functioning: Cycle 35 Number Analyzed 2 participants 6 participants
100.00  (0.000) 75.00  (27.386)
Cognitive Functioning: Cycle 36 Number Analyzed 1 participants 5 participants
100.00 [1]   (NA) 73.33  (34.561)
Cognitive Functioning: Cycle 37 Number Analyzed 1 participants 4 participants
100.00 [1]   (NA) 75.00  (39.675)
Cognitive Functioning: Cycle 38 Number Analyzed 0 participants 4 participants
70.83  (47.871)
Cognitive Functioning: Cycle 39 Number Analyzed 1 participants 3 participants
100.00 [1]   (NA) 72.22  (34.694)
Cognitive Functioning: Cycle 40 Number Analyzed 1 participants 3 participants
83.33 [1]   (NA) 61.11  (34.694)
Cognitive Functioning: Cycle 41 Number Analyzed 0 participants 3 participants
61.11  (41.944)
Cognitive Functioning: Cycle 42 Number Analyzed 0 participants 2 participants
50.00  (70.711)
Cognitive Functioning: Cycle 43 Number Analyzed 0 participants 1 participants
100.00 [1]   (NA)
Cognitive Functioning: EOT Number Analyzed 33 participants 30 participants
83.33  (17.180) 78.33  (23.631)
Social Functioning: Cycle 1 Number Analyzed 61 participants 43 participants
80.87  (23.734) 79.46  (25.675)
Social Functioning: Cycle 2 Number Analyzed 57 participants 41 participants
83.04  (20.288) 82.93  (20.578)
Social Functioning: Cycle 3 Number Analyzed 55 participants 40 participants
79.09  (23.399) 77.08  (26.335)
Social Functioning: Cycle 4 Number Analyzed 50 participants 38 participants
81.67  (21.626) 79.82  (25.160)
Social Functioning: Cycle 5 Number Analyzed 47 participants 34 participants
80.85  (21.697) 79.41  (26.291)
Social Functioning: Cycle 6 Number Analyzed 43 participants 31 participants
80.23  (28.232) 77.42  (28.398)
Social Functioning: Cycle 7 Number Analyzed 39 participants 29 participants
80.34  (22.579) 83.91  (27.271)
Social Functioning: Cycle 8 Number Analyzed 37 participants 25 participants
78.83  (21.748) 80.00  (25.909)
Social Functioning: Cycle 9 Number Analyzed 35 participants 26 participants
77.62  (24.234) 82.05  (23.534)
Social Functioning: Cycle 10 Number Analyzed 35 participants 23 participants
81.43  (20.119) 76.81  (26.939)
Social Functioning: Cycle 11 Number Analyzed 35 participants 24 participants
76.19  (23.321) 81.25  (26.151)
Social Functioning: Cycle 12 Number Analyzed 35 participants 22 participants
75.71  (25.030) 81.82  (27.172)
Social Functioning: Cycle 13 Number Analyzed 34 participants 21 participants
77.94  (25.859) 84.92  (21.670)
Social Functioning: Cycle 14 Number Analyzed 31 participants 19 participants
81.18  (20.968) 79.82  (29.700)
Social Functioning: Cycle 15 Number Analyzed 30 participants 17 participants
76.67  (19.865) 74.51  (31.797)
Social Functioning: Cycle 16 Number Analyzed 27 participants 16 participants
75.93  (24.167) 77.08  (25.000)
Social Functioning: Cycle 17 Number Analyzed 22 participants 15 participants
75.00  (25.066) 75.56  (25.871)
Social Functioning: Cycle 18 Number Analyzed 17 participants 14 participants
76.47  (27.041) 82.14  (28.090)
Social Functioning: Cycle 19 Number Analyzed 12 participants 14 participants
72.22  (24.958) 77.38  (26.640)
Social Functioning: Cycle 20 Number Analyzed 11 participants 13 participants
75.76  (30.151) 83.33  (21.517)
Social Functioning: Cycle 21 Number Analyzed 11 participants 12 participants
71.21  (28.955) 81.94  (26.071)
Social Functioning: Cycle 22 Number Analyzed 11 participants 11 participants
69.70  (33.181) 75.76  (30.151)
Social Functioning: Cycle 23 Number Analyzed 11 participants 10 participants
71.21  (30.814) 78.33  (31.476)
Social Functioning: Cycle 24 Number Analyzed 10 participants 10 participants
63.33  (32.203) 76.67  (30.631)
Social Functioning: Cycle 25 Number Analyzed 10 participants 8 participants
70.00  (39.126) 66.67  (34.503)
Social Functioning: Cycle 26 Number Analyzed 7 participants 7 participants
61.90  (34.311) 88.10  (15.853)
Social Functioning: Cycle 27 Number Analyzed 6 participants 8 participants
58.33  (32.914) 70.83  (33.034)
Social Functioning: Cycle 28 Number Analyzed 7 participants 8 participants
73.81  (38.318) 77.08  (28.084)
Social Functioning: Cycle 29 Number Analyzed 5 participants 7 participants
80.00  (18.257) 71.43  (34.311)
Social Functioning: Cycle 30 Number Analyzed 4 participants 7 participants
75.00  (31.914) 69.05  (36.551)
Social Functioning: Cycle 31 Number Analyzed 2 participants 7 participants
66.67  (47.140) 71.43  (35.635)
Social Functioning: Cycle 32 Number Analyzed 3 participants 6 participants
77.78  (19.245) 66.67  (36.515)
Social Functioning: Cycle 33 Number Analyzed 3 participants 6 participants
66.67  (0.000) 69.44  (30.581)
Social Functioning: Cycle 34 Number Analyzed 3 participants 6 participants
66.67  (0.000) 63.89  (37.143)
Social Functioning: Cycle 35 Number Analyzed 2 participants 6 participants
66.67  (23.570) 72.22  (37.515)
Social Functioning: Cycle 36 Number Analyzed 1 participants 5 participants
100.00 [1]   (NA) 53.33  (36.132)
Social Functioning: Cycle 37 Number Analyzed 1 participants 4 participants
66.67 [1]   (NA) 58.33  (41.944)
Social Functioning: Cycle 38 Number Analyzed 0 participants 4 participants
66.67  (36.004)
Social Functioning: Cycle 39 Number Analyzed 1 participants 3 participants
100.00 [1]   (NA) 44.44  (38.490)
Social Functioning: Cycle 40 Number Analyzed 1 participants 3 participants
66.67 [1]   (NA) 61.11  (38.490)
Social Functioning: Cycle 41 Number Analyzed 0 participants 3 participants
44.44  (25.459)
Social Functioning: Cycle 42 Number Analyzed 0 participants 2 participants
41.67  (35.355)
Social Functioning: Cycle 43 Number Analyzed 0 participants 1 participants
66.67 [1]   (NA)
Social Functioning: EOT Number Analyzed 33 participants 30 participants
73.74  (25.355) 65.00  (29.148)
Fatigue: Cycle 1 Number Analyzed 61 participants 44 participants
21.49  (20.374) 29.42  (17.835)
Fatigue: Cycle 2 Number Analyzed 57 participants 42 participants
24.37  (17.995) 29.10  (19.001)
Fatigue: Cycle 3 Number Analyzed 55 participants 40 participants
26.46  (19.303) 30.28  (22.644)
Fatigue: Cycle 4 Number Analyzed 50 participants 38 participants
24.00  (18.424) 29.53  (24.133)
Fatigue: Cycle 5 Number Analyzed 47 participants 34 participants
26.00  (17.069) 27.61  (23.865)
Fatigue: Cycle 6 Number Analyzed 43 participants 31 participants
25.32  (17.029) 29.93  (25.526)
Fatigue: Cycle 7 Number Analyzed 39 participants 29 participants
26.78  (21.284) 28.35  (24.232)
Fatigue: Cycle 8 Number Analyzed 37 participants 25 participants
27.63  (17.297) 23.11  (18.681)
Fatigue: Cycle 9 Number Analyzed 35 participants 26 participants
26.35  (20.182) 22.22  (20.608)
Fatigue: Cycle 10 Number Analyzed 35 participants 23 participants
26.03  (19.975) 24.64  (23.914)
Fatigue: Cycle 11 Number Analyzed 35 participants 24 participants
27.94  (18.548) 22.45  (20.624)
Fatigue: Cycle 12 Number Analyzed 35 participants 22 participants
26.35  (20.001) 22.22  (23.256)
Fatigue: Cycle 13 Number Analyzed 34 participants 21 participants
25.16  (19.012) 18.52  (15.045)
Fatigue: Cycle 14 Number Analyzed 31 participants 19 participants
24.73  (19.183) 24.56  (20.813)
Fatigue: Cycle 15 Number Analyzed 30 participants 17 participants
24.07  (20.443) 24.84  (24.066)
Fatigue: Cycle 16 Number Analyzed 27 participants 16 participants
27.16  (23.937) 22.92  (17.902)
Fatigue: Cycle 17 Number Analyzed 22 participants 15 participants
28.28  (22.150) 18.52  (18.144)
Fatigue: Cycle 18 Number Analyzed 17 participants 14 participants
26.80  (22.243) 22.22  (17.433)
Fatigue: Cycle 19 Number Analyzed 12 participants 14 participants
34.26  (31.944) 23.02  (20.191)
Fatigue: Cycle 20 Number Analyzed 11 participants 13 participants
34.34  (26.036) 22.22  (18.144)
Fatigue: Cycle 21 Number Analyzed 11 participants 12 participants
34.34  (32.377) 28.70  (21.429)
Fatigue: Cycle 22 Number Analyzed 11 participants 11 participants
31.31  (28.029) 30.30  (27.707)
Fatigue: Cycle 23 Number Analyzed 11 participants 10 participants
39.39  (28.702) 28.89  (25.229)
Fatigue: Cycle 24 Number Analyzed 10 participants 10 participants
36.67  (32.309) 28.89  (26.294)
Fatigue: Cycle 25 Number Analyzed 10 participants 8 participants
40.00  (30.180) 27.78  (21.414)
Fatigue: Cycle 26 Number Analyzed 7 participants 7 participants
44.44  (27.962) 22.22  (14.344)
Fatigue: Cycle 27 Number Analyzed 6 participants 8 participants
50.00  (30.429) 26.39  (22.954)
Fatigue: Cycle 28 Number Analyzed 7 participants 8 participants
42.86  (28.276) 30.56  (26.394)
Fatigue: Cycle 29 Number Analyzed 6 participants 7 participants
35.19  (23.744) 28.57  (21.138)
Fatigue: Cycle 30 Number Analyzed 5 participants 7 participants
24.44  (18.257) 31.75  (27.539)
Fatigue: Cycle 31 Number Analyzed 3 participants 7 participants
22.22  (29.397) 31.75  (29.696)
Fatigue: Cycle 32 Number Analyzed 3 participants 6 participants
18.52  (23.130) 35.19  (12.989)
Fatigue: Cycle 33 Number Analyzed 3 participants 6 participants
22.22  (29.397) 40.74  (20.688)
Fatigue: Cycle 34 Number Analyzed 3 participants 6 participants
37.04  (35.717) 40.74  (16.728)
Fatigue: Cycle 35 Number Analyzed 2 participants 6 participants
33.33  (47.140) 35.19  (16.355)
Fatigue: Cycle 36 Number Analyzed 1 participants 5 participants
0.00 [1]   (NA) 40.00  (14.907)
Fatigue: Cycle 37 Number Analyzed 1 participants 4 participants
0.00 [1]   (NA) 36.11  (21.033)
Fatigue: Cycle 38 Number Analyzed 0 participants 4 participants
44.44  (27.217)
Fatigue: Cycle 39 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 51.85  (33.945)
Fatigue: Cycle 40 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 59.26  (33.945)
Fatigue: Cycle 41 Number Analyzed 0 participants 3 participants
48.15  (23.130)
Fatigue: Cycle 42 Number Analyzed 0 participants 2 participants
44.44  (31.427)
Fatigue: Cycle 43 Number Analyzed 0 participants 1 participants
22.22 [1]   (NA)
Fatigue: EOT Number Analyzed 33 participants 30 participants
33.00  (23.812) 40.56  (28.632)
Nausea and Vomiting: Cycle 1 Number Analyzed 61 participants 44 participants
6.56  (13.010) 7.95  (17.420)
Nausea and Vomiting: Cycle 2 Number Analyzed 57 participants 42 participants
7.31  (12.206) 7.14  (9.123)
Nausea and Vomiting: Cycle 3 Number Analyzed 55 participants 40 participants
7.27  (12.735) 12.08  (19.967)
Nausea and Vomiting: Cycle 4 Number Analyzed 50 participants 38 participants
8.00  (13.569) 4.39  (9.238)
Nausea and Vomiting: Cycle 5 Number Analyzed 47 participants 34 participants
6.38  (12.794) 8.33  (14.935)
Nausea and Vomiting: Cycle 6 Number Analyzed 43 participants 31 participants
6.98  (12.189) 6.99  (11.200)
Nausea and Vomiting: Cycle 7 Number Analyzed 39 participants 29 participants
6.41  (12.458) 6.90  (15.117)
Nausea and Vomiting: Cycle 8 Number Analyzed 37 participants 25 participants
7.66  (15.513) 3.33  (6.804)
Nausea and Vomiting: Cycle 9 Number Analyzed 35 participants 26 participants
9.05  (14.766) 4.49  (10.064)
Nausea and Vomiting: Cycle 10 Number Analyzed 35 participants 23 participants
5.71  (12.088) 4.35  (9.014)
Nausea and Vomiting: Cycle 11 Number Analyzed 35 participants 24 participants
4.76  (10.362) 4.86  (9.167)
Nausea and Vomiting: Cycle 12 Number Analyzed 35 participants 22 participants
4.76  (11.835) 6.06  (8.206)
Nausea and Vomiting: Cycle 13 Number Analyzed 34 participants 21 participants
3.43  (8.970) 2.38  (5.976)
Nausea and Vomiting: Cycle 14 Number Analyzed 31 participants 19 participants
5.38  (9.988) 6.14  (12.681)
Nausea and Vomiting: Cycle 15 Number Analyzed 30 participants 17 participants
7.22  (12.132) 5.88  (16.605)
Nausea and Vomiting: Cycle 16 Number Analyzed 27 participants 16 participants
4.32  (9.906) 3.13  (9.065)
Nausea and Vomiting: Cycle 17 Number Analyzed 22 participants 15 participants
3.03  (8.351) 4.44  (9.894)
Nausea and Vomiting: Cycle 18 Number Analyzed 17 participants 14 participants
4.90  (11.433) 1.19  (4.454)
Nausea and Vomiting: Cycle 19 Number Analyzed 12 participants 14 participants
4.17  (10.360) 4.76  (12.105)
Nausea and Vomiting: Cycle 20 Number Analyzed 11 participants 13 participants
6.06  (15.407) 1.28  (4.623)
Nausea and Vomiting: Cycle 21 Number Analyzed 11 participants 12 participants
4.55  (15.076) 6.94  (19.408)
Nausea and Vomiting: Cycle 22 Number Analyzed 11 participants 11 participants
4.55  (15.076) 9.09  (30.151)
Nausea and Vomiting: Cycle 23 Number Analyzed 11 participants 10 participants
6.06  (15.407) 0.00  (0.000)
Nausea and Vomiting: Cycle 24 Number Analyzed 10 participants 10 participants
6.67  (11.653) 3.33  (7.027)
Nausea and Vomiting: Cycle 25 Number Analyzed 10 participants 8 participants
8.33  (14.164) 0.00  (0.000)
Nausea and Vomiting: Cycle 26 Number Analyzed 7 participants 7 participants
7.14  (8.909) 0.00  (0.000)
Nausea and Vomiting: Cycle 27 Number Analyzed 6 participants 8 participants
11.11  (20.184) 4.17  (11.785)
Nausea and Vomiting: Cycle 28 Number Analyzed 7 participants 8 participants
9.52  (18.898) 2.08  (5.893)
Nausea and Vomiting: Cycle 29 Number Analyzed 6 participants 7 participants
2.78  (6.804) 0.00  (0.000)
Nausea and Vomiting: Cycle 30 Number Analyzed 5 participants 7 participants
0.00  (0.000) 2.38  (6.299)
Nausea and Vomiting: Cycle 31 Number Analyzed 3 participants 7 participants
0.00  (0.000) 0.00  (0.000)
Nausea and Vomiting: Cycle 32 Number Analyzed 3 participants 6 participants
5.56  (9.623) 0.00  (0.000)
Nausea and Vomiting: Cycle 33 Number Analyzed 3 participants 6 participants
22.22  (38.490) 2.78  (6.804)
Nausea and Vomiting: Cycle 34 Number Analyzed 3 participants 6 participants
22.22  (38.490) 8.33  (13.944)
Nausea and Vomiting: Cycle 35 Number Analyzed 2 participants 6 participants
16.67  (23.570) 0.00  (0.000)
Nausea and Vomiting: Cycle 36 Number Analyzed 1 participants 5 participants
0.00 [1]   (NA) 0.00  (0.000)
Nausea and Vomiting: Cycle 37 Number Analyzed 1 participants 4 participants
0.00 [1]   (NA) 4.17  (8.333)
Nausea and Vomiting: Cycle 38 Number Analyzed 0 participants 4 participants
0.00  (0.000)
Nausea and Vomiting: Cycle 39 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 0.00  (0.000)
Nausea and Vomiting: Cycle 40 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 11.11  (19.245)
Nausea and Vomiting: Cycle 41 Number Analyzed 0 participants 3 participants
0.00  (0.000)
Nausea and Vomiting: Cycle 42 Number Analyzed 0 participants 2 participants
0.00  (0.000)
Nausea and Vomiting: Cycle 43 Number Analyzed 0 participants 1 participants
0.00 [1]   (NA)
Nausea and Vomiting: EOT Number Analyzed 33 participants 30 participants
16.16  (21.844) 12.78  (20.846)
Pain: Cycle 1 Number Analyzed 61 participants 44 participants
16.39  (20.067) 18.18  (18.958)
Pain: Cycle 2 Number Analyzed 57 participants 42 participants
16.67  (18.094) 19.05  (20.353)
Pain: Cycle 3 Number Analyzed 55 participants 40 participants
15.76  (18.542) 22.50  (27.099)
Pain: Cycle 4 Number Analyzed 50 participants 38 participants
14.00  (15.922) 23.25  (24.056)
Pain: Cycle 5 Number Analyzed 47 participants 34 participants
15.96  (16.651) 18.14  (22.235)
Pain: Cycle 6 Number Analyzed 43 participants 31 participants
15.89  (17.041) 20.43  (26.073)
Pain: Cycle 7 Number Analyzed 39 participants 29 participants
20.09  (21.690) 22.99  (22.893)
Pain: Cycle 8 Number Analyzed 37 participants 25 participants
17.57  (17.099) 14.67  (16.887)
Pain: Cycle 9 Number Analyzed 35 participants 26 participants
20.48  (19.838) 19.87  (19.447)
Pain: Cycle 10 Number Analyzed 35 participants 23 participants
19.52  (22.682) 18.84  (22.079)
Pain: Cycle 11 Number Analyzed 35 participants 24 participants
19.05  (19.446) 13.89  (18.169)
Pain: Cycle 12 Number Analyzed 35 participants 22 participants
20.48  (22.172) 16.67  (17.817)
Pain: Cycle 13 Number Analyzed 34 participants 21 participants
17.16  (15.616) 15.87  (20.053)
Pain: Cycle 14 Number Analyzed 31 participants 19 participants
14.52  (17.074) 21.05  (19.909)
Pain: Cycle 15 Number Analyzed 30 participants 17 participants
15.00  (23.305) 21.57  (24.127)
Pain: Cycle 16 Number Analyzed 27 participants 16 participants
17.28  (21.917) 15.63  (14.232)
Pain: Cycle 17 Number Analyzed 22 participants 15 participants
18.94  (23.171) 15.56  (17.213)
Pain: Cycle 18 Number Analyzed 17 participants 14 participants
16.67  (22.048) 10.71  (16.803)
Pain: Cycle 19 Number Analyzed 12 participants 14 participants
26.39  (27.941) 13.10  (16.249)
Pain: Cycle 20 Number Analyzed 11 participants 13 participants
25.76  (27.247) 12.82  (15.447)
Pain: Cycle 21 Number Analyzed 11 participants 12 participants
25.76  (29.215) 16.67  (21.320)
Pain: Cycle 22 Number Analyzed 11 participants 11 participants
18.18  (26.304) 21.21  (21.201)
Pain: Cycle 23 Number Analyzed 11 participants 10 participants
21.21  (27.979) 15.00  (22.839)
Pain: Cycle 24 Number Analyzed 10 participants 10 participants
28.33  (26.117) 20.00  (24.595)
Pain: Cycle 25 Number Analyzed 10 participants 8 participants
26.67  (30.631) 16.67  (19.920)
Pain: Cycle 26 Number Analyzed 7 participants 7 participants
38.10  (40.500) 16.67  (19.245)
Pain: Cycle 27 Number Analyzed 6 participants 8 participants
47.22  (35.616) 20.83  (21.362)
Pain: Cycle 28 Number Analyzed 7 participants 8 participants
35.71  (33.923) 22.92  (25.099)
Pain: Cycle 29 Number Analyzed 6 participants 7 participants
19.44  (19.484) 23.81  (26.972)
Pain: Cycle 30 Number Analyzed 5 participants 7 participants
20.00  (21.731) 19.05  (24.398)
Pain: Cycle 31 Number Analyzed 3 participants 7 participants
16.67  (28.868) 26.19  (23.288)
Pain: Cycle 32 Number Analyzed 3 participants 6 participants
16.67  (28.868) 27.78  (31.032)
Pain: Cycle 33 Number Analyzed 3 participants 6 participants
16.67  (28.868) 25.00  (25.276)
Pain: Cycle 34 Number Analyzed 3 participants 6 participants
22.22  (38.490) 27.78  (25.092)
Pain: Cycle 35 Number Analyzed 2 participants 6 participants
25.00  (35.355) 22.22  (13.608)
Pain: Cycle 36 Number Analyzed 1 participants 5 participants
0.00 [1]   (NA) 20.00  (13.944)
Pain: Cycle 37 Number Analyzed 1 participants 4 participants
16.67 [1]   (NA) 29.17  (28.464)
Pain: Cycle 38 Number Analyzed 0 participants 4 participants
29.17  (28.464)
Pain: Cycle 39 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 38.89  (25.459)
Pain: Cycle 40 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 44.44  (19.245)
Pain: Cycle 41 Number Analyzed 0 participants 3 participants
55.56  (41.944)
Pain: Cycle 42 Number Analyzed 0 participants 2 participants
33.33  (47.140)
Pain: Cycle 43 Number Analyzed 0 participants 1 participants
33.33 [1]   (NA)
Pain: EOT Number Analyzed 33 participants 30 participants
23.74  (25.695) 33.89  (32.009)
Dyspnoea: Cycle 1 Number Analyzed 60 participants 44 participants
5.00  (12.003) 7.58  (15.854)
Dyspnoea: Cycle 2 Number Analyzed 57 participants 42 participants
7.02  (15.088) 8.73  (18.123)
Dyspnoea: Cycle 3 Number Analyzed 55 participants 40 participants
6.06  (12.975) 9.17  (21.334)
Dyspnoea: Cycle 4 Number Analyzed 50 participants 38 participants
6.00  (12.936) 13.16  (21.280)
Dyspnoea: Cycle 5 Number Analyzed 47 participants 34 participants
5.67  (14.445) 10.78  (22.801)
Dyspnoea: Cycle 6 Number Analyzed 43 participants 31 participants
6.98  (15.530) 10.75  (24.925)
Dyspnoea: Cycle 7 Number Analyzed 39 participants 29 participants
11.11  (22.076) 10.34  (20.125)
Dyspnoea: Cycle 8 Number Analyzed 37 participants 25 participants
15.32  (21.652) 6.67  (13.608)
Dyspnoea: Cycle 9 Number Analyzed 35 participants 26 participants
9.52  (20.725) 5.13  (12.265)
Dyspnoea: Cycle 10 Number Analyzed 35 participants 23 participants
9.52  (15.278) 10.14  (21.165)
Dyspnoea: Cycle 11 Number Analyzed 35 participants 24 participants
5.71  (12.746) 9.72  (15.477)
Dyspnoea: Cycle 12 Number Analyzed 35 participants 22 participants
8.57  (14.781) 6.06  (13.159)
Dyspnoea: Cycle 13 Number Analyzed 34 participants 21 participants
10.78  (15.829) 12.70  (19.653)
Dyspnoea: Cycle 14 Number Analyzed 31 participants 19 participants
9.68  (15.380) 8.77  (15.080)
Dyspnoea: Cycle 15 Number Analyzed 30 participants 17 participants
8.89  (14.993) 9.80  (15.656)
Dyspnoea: Cycle 16 Number Analyzed 27 participants 16 participants
6.17  (13.195) 6.25  (13.437)
Dyspnoea: Cycle 17 Number Analyzed 22 participants 15 participants
10.61  (15.891) 6.67  (13.801)
Dyspnoea: Cycle 18 Number Analyzed 17 participants 14 participants
7.84  (14.575) 4.76  (12.105)
Dyspnoea: Cycle 19 Number Analyzed 12 participants 14 participants
13.89  (17.164) 4.76  (12.105)
Dyspnoea: Cycle 20 Number Analyzed 11 participants 13 participants
6.06  (13.484) 5.13  (12.518)
Dyspnoea: Cycle 21 Number Analyzed 11 participants 12 participants
12.12  (16.817) 8.33  (15.076)
Dyspnoea: Cycle 22 Number Analyzed 11 participants 11 participants
9.09  (15.570) 9.09  (15.570)
Dyspnoea: Cycle 23 Number Analyzed 11 participants 10 participants
6.06  (13.484) 13.33  (17.213)
Dyspnoea: Cycle 24 Number Analyzed 10 participants 10 participants
6.67  (14.055) 13.33  (17.213)
Dyspnoea: Cycle 25 Number Analyzed 10 participants 8 participants
13.33  (23.307) 8.33  (15.430)
Dyspnoea: Cycle 26 Number Analyzed 7 participants 7 participants
9.52  (16.265) 9.52  (16.265)
Dyspnoea: Cycle 27 Number Analyzed 6 participants 8 participants
11.11  (27.217) 8.33  (15.430)
Dyspnoea: Cycle 28 Number Analyzed 7 participants 8 participants
19.05  (17.817) 12.50  (17.252)
Dyspnoea: Cycle 29 Number Analyzed 6 participants 7 participants
11.11  (27.217) 19.05  (17.817)
Dyspnoea: Cycle 30 Number Analyzed 5 participants 7 participants
6.67  (14.907) 14.29  (17.817)
Dyspnoea: Cycle 31 Number Analyzed 3 participants 7 participants
0.00  (0.000) 9.52  (16.265)
Dyspnoea: Cycle 32 Number Analyzed 3 participants 6 participants
11.11  (19.245) 16.67  (27.889)
Dyspnoea: Cycle 33 Number Analyzed 3 participants 6 participants
22.22  (38.490) 11.11  (17.213)
Dyspnoea: Cycle 34 Number Analyzed 3 participants 6 participants
11.11  (19.245) 16.67  (27.889)
Dyspnoea: Cycle 35 Number Analyzed 2 participants 6 participants
16.67  (23.570) 11.11  (17.213)
Dyspnoea: Cycle 36 Number Analyzed 1 participants 5 participants
0.00 [1]   (NA) 26.67  (27.889)
Dyspnoea: Cycle 37 Number Analyzed 1 participants 4 participants
0.00 [1]   (NA) 8.33  (16.667)
Dyspnoea: Cycle 38 Number Analyzed 0 participants 4 participants
8.33  (16.667)
Dyspnoea: Cycle 39 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 0.00  (0.000)
Dyspnoea: Cycle 40 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 0.00  (0.000)
Dyspnoea: Cycle 41 Number Analyzed 0 participants 3 participants
0.00  (0.000)
Dyspnoea: Cycle 42 Number Analyzed 0 participants 2 participants
16.67  (23.570)
Dyspnoea: Cycle 43 Number Analyzed 0 participants 1 participants
0.00 [1]   (NA)
Dyspnoea: EOT Number Analyzed 33 participants 30 participants
14.14  (16.730) 13.33  (24.132)
Insomnia: Cycle 1 Number Analyzed 61 participants 44 participants
13.11  (20.438) 25.76  (27.715)
Insomnia: Cycle 2 Number Analyzed 57 participants 42 participants
9.36  (16.372) 19.84  (23.350)
Insomnia: Cycle 3 Number Analyzed 55 participants 40 participants
12.12  (17.408) 26.67  (26.366)
Insomnia: Cycle 4 Number Analyzed 50 participants 38 participants
11.33  (19.760) 24.56  (27.601)
Insomnia: Cycle 5 Number Analyzed 47 participants 34 participants
9.22  (19.289) 17.65  (26.253)
Insomnia: Cycle 6 Number Analyzed 43 participants 31 participants
10.85  (18.857) 20.43  (26.774)
Insomnia: Cycle 7 Number Analyzed 39 participants 29 participants
9.40  (18.651) 21.84  (28.558)
Insomnia: Cycle 8 Number Analyzed 37 participants 25 participants
10.81  (20.867) 21.33  (21.257)
Insomnia: Cycle 9 Number Analyzed 35 participants 26 participants
11.43  (19.708) 20.51  (23.242)
Insomnia: Cycle 10 Number Analyzed 35 participants 23 participants
12.38  (18.232) 21.74  (21.576)
Insomnia: Cycle 11 Number Analyzed 35 participants 24 participants
12.38  (18.232) 22.22  (27.217)
Insomnia: Cycle 12 Number Analyzed 35 participants 22 participants
6.67  (15.760) 22.73  (27.958)
Insomnia: Cycle 13 Number Analyzed 34 participants 21 participants
9.80  (15.417) 23.81  (21.455)
Insomnia: Cycle 14 Number Analyzed 31 participants 19 participants
8.60  (17.144) 22.81  (19.413)
Insomnia: Cycle 15 Number Analyzed 29 participants 17 participants
9.20  (17.586) 25.49  (25.082)
Insomnia: Cycle 16 Number Analyzed 27 participants 16 participants
9.88  (20.286) 25.00  (28.545)
Insomnia: Cycle 17 Number Analyzed 22 participants 15 participants
6.06  (16.703) 22.22  (24.125)
Insomnia: Cycle 18 Number Analyzed 17 participants 14 participants
11.76  (16.420) 23.81  (24.209)
Insomnia: Cycle 19 Number Analyzed 12 participants 14 participants
13.89  (22.285) 23.81  (24.209)
Insomnia: Cycle 20 Number Analyzed 11 participants 13 participants
9.09  (15.570) 25.64  (24.167)
Insomnia: Cycle 21 Number Analyzed 11 participants 12 participants
18.18  (22.918) 30.56  (26.432)
Insomnia: Cycle 22 Number Analyzed 11 participants 11 participants
15.15  (22.918) 30.30  (27.707)
Insomnia: Cycle 23 Number Analyzed 11 participants 10 participants
15.15  (17.408) 30.00  (33.148)
Insomnia: Cycle 24 Number Analyzed 10 participants 10 participants
10.00  (22.498) 33.33  (27.217)
Insomnia: Cycle 25 Number Analyzed 10 participants 8 participants
23.33  (27.442) 29.17  (27.817)
Insomnia: Cycle 26 Number Analyzed 7 participants 7 participants
9.52  (16.265) 23.81  (25.198)
Insomnia: Cycle 27 Number Analyzed 6 participants 8 participants
27.78  (38.968) 33.33  (25.198)
Insomnia: Cycle 28 Number Analyzed 7 participants 8 participants
23.81  (25.198) 25.00  (29.547)
Insomnia: Cycle 29 Number Analyzed 6 participants 7 participants
22.22  (27.217) 38.10  (35.635)
Insomnia: Cycle 30 Number Analyzed 5 participants 7 participants
6.67  (14.907) 28.57  (29.991)
Insomnia: Cycle 31 Number Analyzed 3 participants 7 participants
11.11  (19.245) 19.05  (26.227)
Insomnia: Cycle 32 Number Analyzed 3 participants 6 participants
22.22  (19.245) 27.78  (25.092)
Insomnia: Cycle 33 Number Analyzed 3 participants 6 participants
22.22  (19.245) 22.22  (27.217)
Insomnia: Cycle 34 Number Analyzed 3 participants 6 participants
22.22  (38.490) 27.78  (25.092)
Insomnia: Cycle 35 Number Analyzed 2 participants 6 participants
16.67  (23.570) 27.78  (25.092)
Insomnia: Cycle 36 Number Analyzed 1 participants 5 participants
0.00 [1]   (NA) 26.67  (27.889)
Insomnia: Cycle 37 Number Analyzed 1 participants 4 participants
0.00 [1]   (NA) 16.67  (19.245)
Insomnia: Cycle 38 Number Analyzed 0 participants 4 participants
33.33  (27.217)
Insomnia: Cycle 39 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 22.22  (19.245)
Insomnia: Cycle 40 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 33.33  (0.000)
Insomnia: Cycle 41 Number Analyzed 0 participants 3 participants
22.22  (19.245)
Insomnia: Cycle 42 Number Analyzed 0 participants 2 participants
16.67  (23.570)
Insomnia: Cycle 43 Number Analyzed 0 participants 1 participants
33.33 [1]   (NA)
Insomnia: EOT Number Analyzed 33 participants 30 participants
16.16  (26.512) 25.56  (33.543)
Appetite Loss: Cycle 1 Number Analyzed 61 participants 44 participants
12.57  (21.225) 15.91  (23.282)
Appetite Loss: Cycle 2 Number Analyzed 57 participants 42 participants
16.96  (21.009) 18.25  (22.333)
Appetite Loss: Cycle 3 Number Analyzed 55 participants 40 participants
13.94  (18.912) 20.83  (28.929)
Appetite Loss: Cycle 4 Number Analyzed 50 participants 38 participants
14.00  (24.365) 16.67  (26.565)
Appetite Loss: Cycle 5 Number Analyzed 47 participants 34 participants
10.64  (20.974) 15.69  (28.704)
Appetite Loss: Cycle 6 Number Analyzed 43 participants 31 participants
10.85  (20.212) 18.28  (30.839)
Appetite Loss: Cycle 7 Number Analyzed 39 participants 29 participants
14.53  (22.679) 14.94  (28.986)
Appetite Loss: Cycle 8 Number Analyzed 37 participants 25 participants
16.22  (25.606) 14.67  (25.604)
Appetite Loss: Cycle 9 Number Analyzed 35 participants 26 participants
14.29  (18.587) 14.10  (26.954)
Appetite Loss: Cycle 10 Number Analyzed 35 participants 23 participants
13.33  (21.693) 17.39  (28.194)
Appetite Loss: Cycle 11 Number Analyzed 35 participants 24 participants
15.24  (21.907) 8.33  (22.522)
Appetite Loss: Cycle 12 Number Analyzed 35 participants 22 participants
13.33  (25.820) 12.12  (24.224)
Appetite Loss: Cycle 13 Number Analyzed 34 participants 21 participants
13.73  (21.893) 7.94  (14.548)
Appetite Loss: Cycle 14 Number Analyzed 31 participants 19 participants
10.75  (21.751) 10.53  (19.413)
Appetite Loss: Cycle 15 Number Analyzed 30 participants 17 participants
13.33  (24.132) 15.69  (29.149)
Appetite Loss: Cycle 16 Number Analyzed 27 participants 16 participants
13.58  (23.130) 8.33  (19.245)
Appetite Loss: Cycle 17 Number Analyzed 22 participants 15 participants
10.61  (23.874) 6.67  (18.687)
Appetite Loss: Cycle 18 Number Analyzed 17 participants 14 participants
17.65  (29.149) 9.52  (20.375)
Appetite Loss: Cycle 19 Number Analyzed 12 participants 14 participants
19.44  (33.207) 9.52  (27.514)
Appetite Loss: Cycle 20 Number Analyzed 11 participants 13 participants
21.21  (34.230) 5.13  (12.518)
Appetite Loss: Cycle 21 Number Analyzed 11 participants 12 participants
21.21  (34.230) 16.67  (22.473)
Appetite Loss: Cycle 22 Number Analyzed 11 participants 11 participants
18.18  (31.140) 15.15  (22.918)
Appetite Loss: Cycle 23 Number Analyzed 11 participants 10 participants
18.18  (31.140) 10.00  (22.498)
Appetite Loss: Cycle 24 Number Analyzed 10 participants 10 participants
23.33  (35.312) 13.33  (23.307)
Appetite Loss: Cycle 25 Number Analyzed 10 participants 8 participants
23.33  (41.722) 8.33  (23.570)
Appetite Loss: Cycle 26 Number Analyzed 7 participants 7 participants
38.10  (48.795) 4.76  (12.599)
Appetite Loss: Cycle 27 Number Analyzed 6 participants 8 participants
33.33  (42.164) 12.50  (35.355)
Appetite Loss: Cycle 28 Number Analyzed 7 participants 8 participants
28.57  (40.500) 16.67  (35.635)
Appetite Loss: Cycle 29 Number Analyzed 6 participants 7 participants
11.11  (27.217) 4.76  (12.599)
Appetite Loss: Cycle 30 Number Analyzed 5 participants 7 participants
0.00  (0.000) 4.76  (12.599)
Appetite Loss: Cycle 31 Number Analyzed 3 participants 7 participants
0.00  (0.000) 9.52  (25.198)
Appetite Loss: Cycle 32 Number Analyzed 3 participants 6 participants
11.11  (19.245) 16.67  (27.889)
Appetite Loss: Cycle 33 Number Analyzed 3 participants 6 participants
22.22  (38.490) 16.67  (27.889)
Appetite Loss: Cycle 34 Number Analyzed 3 participants 6 participants
33.33  (57.735) 27.78  (32.773)
Appetite Loss: Cycle 35 Number Analyzed 2 participants 6 participants
33.33  (47.140) 11.11  (27.217)
Appetite Loss: Cycle 36 Number Analyzed 1 participants 5 participants
0.00 [1]   (NA) 0.00  (0.000)
Appetite Loss: Cycle 37 Number Analyzed 1 participants 4 participants
0.00 [1]   (NA) 16.67  (19.245)
Appetite Loss: Cycle 38 Number Analyzed 0 participants 4 participants
16.67  (19.245)
Appetite Loss: Cycle 39 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 11.11  (19.245)
Appetite Loss: Cycle 40 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 11.11  (19.245)
Appetite Loss: Cycle 41 Number Analyzed 0 participants 3 participants
22.22  (38.490)
Appetite Loss: Cycle 42 Number Analyzed 0 participants 2 participants
16.67  (23.570)
Appetite Loss: Cycle 43 Number Analyzed 0 participants 1 participants
0.00 [1]   (NA)
Appetite Loss: EOT Number Analyzed 33 participants 30 participants
27.27  (34.816) 26.67  (32.044)
Constipation: Cycle 1 Number Analyzed 61 participants 44 participants
7.10  (17.336) 9.09  (18.135)
Constipation: Cycle 2 Number Analyzed 57 participants 42 participants
3.51  (10.321) 13.49  (26.605)
Constipation: Cycle 3 Number Analyzed 55 participants 40 participants
7.27  (15.303) 4.17  (13.477)
Constipation: Cycle 4 Number Analyzed 50 participants 38 participants
6.67  (15.058) 5.26  (12.318)
Constipation: Cycle 5 Number Analyzed 47 participants 34 participants
3.55  (12.499) 2.94  (12.627)
Constipation: Cycle 6 Number Analyzed 43 participants 31 participants
3.88  (10.812) 2.15  (8.324)
Constipation: Cycle 7 Number Analyzed 39 participants 29 participants
3.42  (10.245) 5.75  (17.970)
Constipation: Cycle 8 Number Analyzed 37 participants 25 participants
3.60  (13.109) 4.00  (14.657)
Constipation: Cycle 9 Number Analyzed 35 participants 26 participants
6.67  (15.760) 3.85  (14.382)
Constipation: Cycle 10 Number Analyzed 35 participants 23 participants
2.86  (9.468) 5.80  (16.368)
Constipation: Cycle 11 Number Analyzed 35 participants 24 participants
3.81  (13.459) 2.78  (9.411)
Constipation: Cycle 12 Number Analyzed 35 participants 22 participants
5.71  (12.746) 4.55  (11.708)
Constipation: Cycle 13 Number Analyzed 34 participants 21 participants
2.94  (9.597) 1.59  (7.274)
Constipation: Cycle 14 Number Analyzed 31 participants 19 participants
1.08  (5.987) 3.51  (10.510)
Constipation: Cycle 15 Number Analyzed 30 participants 17 participants
2.22  (8.457) 3.92  (16.169)
Constipation: Cycle 16 Number Analyzed 27 participants 16 participants
2.47  (8.896) 6.25  (13.437)
Constipation: Cycle 17 Number Analyzed 22 participants 15 participants
6.06  (13.159) 2.22  (8.607)
Constipation: Cycle 18 Number Analyzed 17 participants 14 participants
3.92  (11.070) 4.76  (12.105)
Constipation: Cycle 19 Number Analyzed 12 participants 14 participants
0.00  (0.000) 9.52  (20.375)
Constipation: Cycle 20 Number Analyzed 11 participants 13 participants
0.00  (0.000) 0.00  (0.000)
Constipation: Cycle 21 Number Analyzed 11 participants 12 participants
0.00  (0.000) 2.78  (9.623)
Constipation: Cycle 22 Number Analyzed 11 participants 11 participants
0.00  (0.000) 12.12  (30.814)
Constipation: Cycle 23 Number Analyzed 11 participants 10 participants
0.00  (0.000) 3.33  (10.541)
Constipation: Cycle 24 Number Analyzed 10 participants 10 participants
0.00  (0.000) 6.67  (14.055)
Constipation: Cycle 25 Number Analyzed 10 participants 8 participants
3.33  (10.541) 0.00  (0.000)
Constipation: Cycle 26 Number Analyzed 7 participants 7 participants
0.00  (0.000) 4.76  (12.599)
Constipation: Cycle 27 Number Analyzed 6 participants 8 participants
5.56  (13.608) 4.17  (11.785)
Constipation: Cycle 28 Number Analyzed 7 participants 8 participants
4.76  (12.599) 4.17  (11.785)
Constipation: Cycle 29 Number Analyzed 5 participants 7 participants
0.00  (0.000) 4.76  (12.599)
Constipation: Cycle 30 Number Analyzed 4 participants 7 participants
0.00  (0.000) 4.76  (12.599)
Constipation: Cycle 31 Number Analyzed 2 participants 7 participants
0.00  (0.000) 4.76  (12.599)
Constipation: Cycle 32 Number Analyzed 3 participants 6 participants
0.00  (0.000) 0.00  (0.000)
Constipation: Cycle 33 Number Analyzed 3 participants 6 participants
0.00  (0.000) 5.56  (13.608)
Constipation: Cycle 34 Number Analyzed 3 participants 6 participants
0.00  (0.000) 5.56  (13.608)
Constipation: Cycle 35 Number Analyzed 2 participants 6 participants
0.00  (0.000) 5.56  (13.608)
Constipation: Cycle 36 Number Analyzed 1 participants 5 participants
0.00 [1]   (NA) 13.33  (29.814)
Constipation: Cycle 37 Number Analyzed 1 participants 4 participants
0.00 [1]   (NA) 0.00  (0.000)
Constipation: Cycle 38 Number Analyzed 0 participants 4 participants
0.00  (0.000)
Constipation: Cycle 39 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 11.11  (19.245)
Constipation: Cycle 40 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 0.00  (0.000)
Constipation: Cycle 41 Number Analyzed 0 participants 3 participants
0.00  (0.000)
Constipation: Cycle 42 Number Analyzed 0 participants 2 participants
0.00  (0.000)
Constipation: Cycle 43 Number Analyzed 0 participants 1 participants
0.00 [1]   (NA)
Constipation: EOT Number Analyzed 33 participants 30 participants
10.10  (19.516) 3.33  (10.171)
Diarrhoea: Cycle 1 Number Analyzed 61 participants 43 participants
14.21  (22.327) 11.63  (17.644)
Diarrhoea: Cycle 2 Number Analyzed 57 participants 41 participants
18.13  (26.027) 17.07  (25.951)
Diarrhoea: Cycle 3 Number Analyzed 55 participants 40 participants
16.36  (24.740) 24.17  (25.021)
Diarrhoea: Cycle 4 Number Analyzed 50 participants 38 participants
22.00  (27.446) 15.79  (21.556)
Diarrhoea: Cycle 5 Number Analyzed 47 participants 34 participants
22.70  (26.105) 21.57  (23.039)
Diarrhoea: Cycle 6 Number Analyzed 43 participants 31 participants
24.03  (29.390) 22.58  (21.751)
Diarrhoea: Cycle 7 Number Analyzed 39 participants 29 participants
29.06  (27.762) 25.29  (29.080)
Diarrhoea: Cycle 8 Number Analyzed 37 participants 25 participants
26.13  (27.369) 20.00  (28.868)
Diarrhoea: Cycle 9 Number Analyzed 35 participants 26 participants
30.48  (30.648) 29.49  (33.102)
Diarrhoea: Cycle 10 Number Analyzed 35 participants 23 participants
24.76  (26.000) 27.54  (29.563)
Diarrhoea: Cycle 11 Number Analyzed 35 participants 24 participants
23.81  (25.012) 23.61  (23.008)
Diarrhoea: Cycle 12 Number Analyzed 35 participants 22 participants
21.90  (22.785) 18.18  (22.366)
Diarrhoea: Cycle 13 Number Analyzed 34 participants 21 participants
21.57  (21.528) 19.05  (27.021)
Diarrhoea: Cycle 14 Number Analyzed 31 participants 19 participants
23.66  (23.084) 19.30  (20.233)
Diarrhoea: Cycle 15 Number Analyzed 30 participants 17 participants
21.11  (23.947) 25.49  (22.140)
Diarrhoea: Cycle 16 Number Analyzed 27 participants 16 participants
18.52  (25.036) 20.83  (20.638)
Diarrhoea: Cycle 17 Number Analyzed 22 participants 15 participants
21.21  (19.370) 15.56  (24.774)
Diarrhoea: Cycle 18 Number Analyzed 17 participants 14 participants
25.49  (27.712) 19.05  (25.198)
Diarrhoea: Cycle 19 Number Analyzed 12 participants 14 participants
13.89  (17.164) 19.05  (21.540)
Diarrhoea: Cycle 20 Number Analyzed 11 participants 13 participants
27.27  (20.101) 23.08  (25.036)
Diarrhoea: Cycle 21 Number Analyzed 11 participants 12 participants
33.33  (29.814) 25.00  (28.868)
Diarrhoea: Cycle 22 Number Analyzed 11 participants 11 participants
18.18  (31.140) 21.21  (26.968)
Diarrhoea: Cycle 23 Number Analyzed 11 participants 10 participants
24.24  (33.635) 26.67  (30.631)
Diarrhoea: Cycle 24 Number Analyzed 10 participants 10 participants
23.33  (22.498) 23.33  (31.623)
Diarrhoea: Cycle 25 Number Analyzed 10 participants 8 participants
16.67  (17.568) 29.17  (27.817)
Diarrhoea: Cycle 26 Number Analyzed 7 participants 7 participants
19.05  (26.227) 28.57  (29.991)
Diarrhoea: Cycle 27 Number Analyzed 6 participants 8 participants
22.22  (17.213) 37.50  (33.034)
Diarrhoea: Cycle 28 Number Analyzed 7 participants 8 participants
14.29  (17.817) 29.17  (27.817)
Diarrhoea: Cycle 29 Number Analyzed 5 participants 7 participants
0.00  (0.000) 28.57  (29.991)
Diarrhoea: Cycle 30 Number Analyzed 4 participants 7 participants
0.00  (0.000) 38.10  (23.002)
Diarrhoea: Cycle 31 Number Analyzed 2 participants 7 participants
0.00  (0.000) 33.33  (27.217)
Diarrhoea: Cycle 32 Number Analyzed 3 participants 6 participants
22.22  (19.245) 50.00  (27.889)
Diarrhoea: Cycle 33 Number Analyzed 3 participants 6 participants
11.11  (19.245) 50.00  (27.889)
Diarrhoea: Cycle 34 Number Analyzed 3 participants 6 participants
33.33  (33.333) 44.44  (27.217)
Diarrhoea: Cycle 35 Number Analyzed 2 participants 6 participants
16.67  (23.570) 38.89  (32.773)
Diarrhoea: Cycle 36 Number Analyzed 1 participants 5 participants
0.00 [1]   (NA) 40.00  (43.461)
Diarrhoea: Cycle 37 Number Analyzed 1 participants 4 participants
0.00 [1]   (NA) 25.00  (31.914)
Diarrhoea: Cycle 38 Number Analyzed 0 participants 4 participants
41.67  (31.914)
Diarrhoea: Cycle 39 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 33.33  (33.333)
Diarrhoea: Cycle 40 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 44.44  (38.490)
Diarrhoea: Cycle 41 Number Analyzed 0 participants 3 participants
44.44  (38.490)
Diarrhoea: Cycle 42 Number Analyzed 0 participants 2 participants
50.00  (23.570)
Diarrhoea: Cycle 43 Number Analyzed 0 participants 1 participants
66.67 [1]   (NA)
Diarrhoea: EOT Number Analyzed 33 participants 30 participants
24.24  (29.194) 17.78  (24.343)
Financial Difficulties: Cycle 1 Number Analyzed 61 participants 43 participants
25.68  (35.691) 31.01  (33.646)
Financial Difficulties: Cycle 2 Number Analyzed 57 participants 41 participants
23.39  (28.843) 21.95  (26.468)
Financial Difficulties: Cycle 3 Number Analyzed 55 participants 40 participants
23.03  (30.002) 30.00  (34.427)
Financial Difficulties: Cycle 4 Number Analyzed 50 participants 38 participants
24.00  (30.147) 28.95  (27.037)
Financial Difficulties: Cycle 5 Number Analyzed 47 participants 34 participants
26.24  (34.005) 25.49  (29.654)
Financial Difficulties: Cycle 6 Number Analyzed 43 participants 31 participants
27.13  (35.078) 26.88  (31.528)
Financial Difficulties: Cycle 7 Number Analyzed 39 participants 29 participants
29.06  (31.696) 27.59  (32.206)
Financial Difficulties: Cycle 8 Number Analyzed 37 participants 25 participants
30.63  (32.753) 25.33  (29.313)
Financial Difficulties: Cycle 9 Number Analyzed 35 participants 26 participants
22.86  (28.892) 20.51  (29.929)
Financial Difficulties: Cycle 10 Number Analyzed 35 participants 23 participants
25.71  (28.105) 24.64  (30.513)
Financial Difficulties: Cycle 11 Number Analyzed 35 participants 24 participants
26.67  (27.771) 23.61  (28.622)
Financial Difficulties: Cycle 12 Number Analyzed 35 participants 22 participants
26.67  (30.033) 19.70  (26.546)
Financial Difficulties: Cycle 13 Number Analyzed 34 participants 21 participants
23.53  (27.864) 19.05  (30.861)
Financial Difficulties: Cycle 14 Number Analyzed 31 participants 19 participants
23.66  (28.795) 17.54  (28.040)
Financial Difficulties: Cycle 15 Number Analyzed 30 participants 17 participants
21.11  (22.289) 19.61  (29.009)
Financial Difficulties: Cycle 16 Number Analyzed 27 participants 16 participants
22.22  (22.646) 18.75  (29.736)
Financial Difficulties: Cycle 17 Number Analyzed 22 participants 15 participants
19.70  (24.471) 15.56  (27.794)
Financial Difficulties: Cycle 18 Number Analyzed 17 participants 14 participants
17.65  (29.149) 16.67  (21.681)
Financial Difficulties: Cycle 19 Number Analyzed 12 participants 14 participants
22.22  (32.824) 14.29  (17.118)
Financial Difficulties: Cycle 20 Number Analyzed 11 participants 13 participants
15.15  (22.918) 15.38  (29.235)
Financial Difficulties: Cycle 21 Number Analyzed 11 participants 12 participants
24.24  (33.635) 16.67  (30.151)
Financial Difficulties: Cycle 22 Number Analyzed 11 participants 11 participants
18.18  (27.340) 15.15  (22.918)
Financial Difficulties: Cycle 23 Number Analyzed 11 participants 10 participants
15.15  (22.918) 20.00  (32.203)
Financial Difficulties: Cycle 24 Number Analyzed 10 participants 10 participants
20.00  (28.109) 16.67  (32.394)
Financial Difficulties: Cycle 25 Number Analyzed 10 participants 8 participants
16.67  (28.328) 29.17  (37.533)
Financial Difficulties: Cycle 26 Number Analyzed 7 participants 7 participants
23.81  (31.706) 28.57  (40.500)
Financial Difficulties: Cycle 27 Number Analyzed 6 participants 8 participants
16.67  (27.889) 20.83  (35.355)
Financial Difficulties: Cycle 28 Number Analyzed 7 participants 8 participants
19.05  (26.227) 20.83  (35.355)
Financial Difficulties: Cycle 29 Number Analyzed 5 participants 7 participants
13.33  (29.814) 19.05  (37.796)
Financial Difficulties: Cycle 30 Number Analyzed 4 participants 7 participants
16.67  (33.333) 19.05  (37.796)
Financial Difficulties: Cycle 31 Number Analyzed 2 participants 7 participants
33.33  (47.140) 19.05  (37.796)
Financial Difficulties: Cycle 32 Number Analyzed 3 participants 6 participants
22.22  (38.490) 22.22  (40.369)
Financial Difficulties: Cycle 33 Number Analyzed 3 participants 6 participants
33.33  (33.333) 22.22  (40.369)
Financial Difficulties: Cycle 34 Number Analyzed 3 participants 6 participants
22.22  (19.245) 22.22  (40.369)
Financial Difficulties: Cycle 35 Number Analyzed 2 participants 6 participants
50.00  (23.570) 22.22  (40.369)
Financial Difficulties: Cycle 36 Number Analyzed 1 participants 5 participants
0.00 [1]   (NA) 20.00  (44.721)
Financial Difficulties: Cycle 37 Number Analyzed 1 participants 4 participants
33.33 [1]   (NA) 8.33  (16.667)
Financial Difficulties: Cycle 38 Number Analyzed 0 participants 4 participants
8.33  (16.667)
Financial Difficulties: Cycle 39 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 11.11  (19.245)
Financial Difficulties: Cycle 40 Number Analyzed 1 participants 3 participants
33.33 [1]   (NA) 11.11  (19.245)
Financial Difficulties: Cycle 41 Number Analyzed 0 participants 3 participants
22.22  (19.245)
Financial Difficulties: Cycle 42 Number Analyzed 0 participants 2 participants
0.00  (0.000)
Financial Difficulties: Cycle 43 Number Analyzed 0 participants 1 participants
0.00 [1]   (NA)
Financial Difficulties: EOT Number Analyzed 33 participants 30 participants
30.30  (29.302) 23.33  (26.479)
[1]
Standard deviation was not estimable since only 1 participant was evaluable.
13.Secondary Outcome
Title Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21)
Hide Description EORTC QLQ-GI-NET 21 was a 21-item questionnaire. These 21 questions assesses endocrine symptoms, gastrointestinal (G.I.) symptoms, treatment related symptoms, social functioning, disease related worries, muscle/bone pain, sexual function, information/communication function and body image. Each item was answered on a 4-point scale: 1 =not at all, 2 =a little, 3 =quite a bit, 4 =very much; where higher scores indicated more severe symptoms/problems. Scores averaged, transformed to 0-100 scale; higher score=more severe symptoms.
Time Frame Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, End of treatment (up to maximum duration of 1226 days)
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not. Here, “0 participants” in the “number analyzed” field signifies none of the participants were evaluable in the given group at this time point, hence data was not reported.
Arm/Group Title Sunitinib: Treatment Naive Cohort Sunitinib: Later-Line Cohort
Hide Arm/Group Description:
Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.
Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Number of Participants Analyzed 61 45
Mean (Standard Deviation)
Unit of Measure: units on a scale
Endocrine Symptoms: Cycle 1 Number Analyzed 61 participants 44 participants
9.47  (14.746) 15.66  (20.378)
Endocrine Symptoms: Cycle 2 Number Analyzed 57 participants 41 participants
9.94  (14.347) 14.91  (16.407)
Endocrine Symptoms: Cycle 3 Number Analyzed 55 participants 40 participants
14.75  (20.066) 11.67  (14.443)
Endocrine Symptoms: Cycle 4 Number Analyzed 50 participants 37 participants
12.67  (15.227) 12.31  (14.531)
Endocrine Symptoms: Cycle 5 Number Analyzed 47 participants 33 participants
12.29  (13.752) 8.08  (12.507)
Endocrine Symptoms: Cycle 6 Number Analyzed 43 participants 31 participants
13.18  (16.490) 9.32  (13.788)
Endocrine Symptoms: Cycle 7 Number Analyzed 39 participants 29 participants
12.82  (14.315) 12.07  (16.538)
Endocrine Symptoms: Cycle 8 Number Analyzed 37 participants 25 participants
13.81  (18.408) 10.67  (14.515)
Endocrine Symptoms: Cycle 9 Number Analyzed 35 participants 26 participants
10.16  (14.851) 11.11  (14.741)
Endocrine Symptoms: Cycle 10 Number Analyzed 35 participants 23 participants
10.16  (13.304) 14.01  (18.416)
Endocrine Symptoms: Cycle 11 Number Analyzed 35 participants 24 participants
13.02  (16.934) 13.43  (19.653)
Endocrine Symptoms: Cycle 12 Number Analyzed 35 participants 22 participants
12.06  (16.693) 11.62  (17.644)
Endocrine Symptoms: Cycle 13 Number Analyzed 34 participants 21 participants
10.46  (14.459) 11.64  (15.899)
Endocrine Symptoms: Cycle 14 Number Analyzed 31 participants 19 participants
12.19  (16.815) 14.62  (18.538)
Endocrine Symptoms: Cycle 15 Number Analyzed 30 participants 17 participants
13.33  (18.082) 15.69  (18.864)
Endocrine Symptoms: Cycle 16 Number Analyzed 27 participants 16 participants
10.70  (16.155) 9.03  (11.631)
Endocrine Symptoms: Cycle 17 Number Analyzed 22 participants 15 participants
12.12  (18.753) 8.89  (10.457)
Endocrine Symptoms: Cycle 18 Number Analyzed 17 participants 14 participants
11.11  (18.840) 11.90  (14.756)
Endocrine Symptoms: Cycle 19 Number Analyzed 12 participants 14 participants
14.81  (21.364) 6.35  (11.293)
Endocrine Symptoms: Cycle 20 Number Analyzed 11 participants 13 participants
15.15  (20.045) 11.11  (17.568)
Endocrine Symptoms: Cycle 21 Number Analyzed 11 participants 12 participants
20.20  (20.975) 9.26  (12.385)
Endocrine Symptoms: Cycle 22 Number Analyzed 11 participants 11 participants
14.14  (19.303) 16.16  (21.294)
Endocrine Symptoms: Cycle 23 Number Analyzed 11 participants 10 participants
18.18  (15.131) 13.33  (16.397)
Endocrine Symptoms: Cycle 24 Number Analyzed 10 participants 10 participants
22.22  (31.427) 13.33  (14.628)
Endocrine Symptoms: Cycle 25 Number Analyzed 10 participants 8 participants
16.67  (23.570) 8.33  (12.944)
Endocrine Symptoms: Cycle 26 Number Analyzed 7 participants 7 participants
22.22  (27.962) 7.94  (13.929)
Endocrine Symptoms: Cycle 27 Number Analyzed 6 participants 8 participants
22.22  (28.109) 9.72  (12.511)
Endocrine Symptoms: Cycle 28 Number Analyzed 7 participants 8 participants
19.05  (29.197) 12.50  (18.245)
Endocrine Symptoms: Cycle 29 Number Analyzed 6 participants 7 participants
12.96  (12.989) 11.11  (12.830)
Endocrine Symptoms: Cycle 30 Number Analyzed 5 participants 7 participants
8.89  (9.296) 14.29  (13.929)
Endocrine Symptoms: Cycle 31 Number Analyzed 3 participants 7 participants
14.81  (6.415) 12.70  (11.878)
Endocrine Symptoms: Cycle 32 Number Analyzed 3 participants 6 participants
7.41  (12.830) 14.81  (13.456)
Endocrine Symptoms: Cycle 33 Number Analyzed 3 participants 6 participants
11.11  (0.000) 16.67  (11.653)
Endocrine Symptoms: Cycle 34 Number Analyzed 3 participants 6 participants
18.52  (6.415) 20.37  (23.744)
Endocrine Symptoms: Cycle 35 Number Analyzed 2 participants 6 participants
22.22  (0.000) 16.67  (16.851)
Endocrine Symptoms: Cycle 36 Number Analyzed 1 participants 5 participants
22.22 [1]   (NA) 17.78  (18.592)
Endocrine Symptoms: Cycle 37 Number Analyzed 1 participants 4 participants
22.22 [1]   (NA) 5.56  (11.111)
Endocrine Symptoms: Cycle 38 Number Analyzed 0 participants 4 participants
8.33  (10.638)
Endocrine Symptoms: Cycle 39 Number Analyzed 1 participants 3 participants
22.22 [1]   (NA) 11.11  (11.111)
Endocrine Symptoms: Cycle 40 Number Analyzed 1 participants 3 participants
22.22 [1]   (NA) 11.11  (11.111)
Endocrine Symptoms: Cycle 41 Number Analyzed 0 participants 3 participants
11.11  (11.111)
Endocrine Symptoms: Cycle 42 Number Analyzed 0 participants 2 participants
0.00  (0.000)
Endocrine Symptoms: Cycle 43 Number Analyzed 0 participants 1 participants
0.00 [1]   (NA)
Endocrine Symptoms: EOT Number Analyzed 33 participants 29 participants
13.80  (15.474) 11.11  (16.534)
Gastrointestinal Symptoms: Cycle 1 Number Analyzed 61 participants 44 participants
15.41  (14.633) 15.30  (13.301)
Gastrointestinal Symptoms: Cycle 2 Number Analyzed 57 participants 41 participants
17.66  (14.057) 17.72  (13.631)
Gastrointestinal Symptoms: Cycle 3 Number Analyzed 55 participants 40 participants
20.24  (17.543) 19.50  (16.702)
Gastrointestinal Symptoms: Cycle 4 Number Analyzed 50 participants 38 participants
19.47  (16.814) 19.30  (17.315)
Gastrointestinal Symptoms: Cycle 5 Number Analyzed 47 participants 33 participants
15.18  (13.528) 21.01  (17.569)
Gastrointestinal Symptoms: Cycle 6 Number Analyzed 43 participants 31 participants
18.76  (16.982) 21.51  (20.273)
Gastrointestinal Symptoms: Cycle 7 Number Analyzed 39 participants 29 participants
18.63  (19.114) 20.23  (18.728)
Gastrointestinal Symptoms: Cycle 8 Number Analyzed 37 participants 25 participants
20.72  (19.359) 19.47  (15.743)
Gastrointestinal Symptoms: Cycle 9 Number Analyzed 35 participants 26 participants
18.86  (18.040) 19.49  (17.681)
Gastrointestinal Symptoms: Cycle 10 Number Analyzed 35 participants 23 participants
18.38  (17.916) 19.78  (18.315)
Gastrointestinal Symptoms: Cycle 11 Number Analyzed 35 participants 24 participants
18.86  (15.295) 16.94  (17.360)
Gastrointestinal Symptoms: Cycle 12 Number Analyzed 35 participants 22 participants
18.86  (18.040) 18.79  (20.741)
Gastrointestinal Symptoms: Cycle 13 Number Analyzed 34 participants 21 participants
18.04  (17.641) 14.60  (13.600)
Gastrointestinal Symptoms: Cycle 14 Number Analyzed 31 participants 19 participants
18.06  (18.871) 16.49  (13.943)
Gastrointestinal Symptoms: Cycle 15 Number Analyzed 30 participants 17 participants
19.56  (17.934) 22.35  (22.966)
Gastrointestinal Symptoms: Cycle 16 Number Analyzed 27 participants 16 participants
17.53  (17.458) 17.50  (14.782)
Gastrointestinal Symptoms: Cycle 17 Number Analyzed 22 participants 15 participants
18.18  (19.099) 13.78  (12.206)
Gastrointestinal Symptoms: Cycle 18 Number Analyzed 17 participants 14 participants
24.31  (20.942) 15.71  (12.433)
Gastrointestinal Symptoms: Cycle 19 Number Analyzed 12 participants 14 participants
23.89  (21.360) 20.48  (20.500)
Gastrointestinal Symptoms: Cycle 20 Number Analyzed 11 participants 13 participants
25.45  (22.473) 16.41  (15.303)
Gastrointestinal Symptoms: Cycle 21 Number Analyzed 11 participants 12 participants
29.09  (22.759) 17.22  (16.927)
Gastrointestinal Symptoms: Cycle 22 Number Analyzed 11 participants 11 participants
23.03  (21.574) 18.18  (18.641)
Gastrointestinal Symptoms: Cycle 23 Number Analyzed 11 participants 10 participants
27.27  (26.408) 20.00  (18.856)
Gastrointestinal Symptoms: Cycle 24 Number Analyzed 10 participants 10 participants
26.00  (20.476) 21.33  (18.539)
Gastrointestinal Symptoms: Cycle 25 Number Analyzed 10 participants 8 participants
24.67  (19.386) 23.33  (17.090)
Gastrointestinal Symptoms: Cycle 26 Number Analyzed 7 participants 7 participants
30.48  (17.152) 20.95  (15.601)
Gastrointestinal Symptoms: Cycle 27 Number Analyzed 6 participants 8 participants
34.44  (28.415) 25.83  (20.912)
Gastrointestinal Symptoms: Cycle 28 Number Analyzed 7 participants 8 participants
28.57  (23.637) 23.96  (20.967)
Gastrointestinal Symptoms: Cycle 29 Number Analyzed 6 participants 7 participants
22.22  (5.443) 28.57  (17.090)
Gastrointestinal Symptoms: Cycle 30 Number Analyzed 5 participants 7 participants
18.67  (15.202) 21.90  (17.518)
Gastrointestinal Symptoms: Cycle 31 Number Analyzed 3 participants 7 participants
24.44  (26.943) 22.86  (19.572)
Gastrointestinal Symptoms: Cycle 32 Number Analyzed 3 participants 6 participants
22.22  (27.756) 27.78  (19.052)
Gastrointestinal Symptoms: Cycle 33 Number Analyzed 3 participants 6 participants
26.67  (35.277) 23.33  (17.256)
Gastrointestinal Symptoms: Cycle 34 Number Analyzed 3 participants 6 participants
20.00  (29.059) 28.89  (15.587)
Gastrointestinal Symptoms: Cycle 35 Number Analyzed 2 participants 6 participants
23.33  (32.998) 20.00  (15.202)
Gastrointestinal Symptoms: Cycle 36 Number Analyzed 1 participants 5 participants
0.00 [1]   (NA) 17.33  (15.348)
Gastrointestinal Symptoms: Cycle 37 Number Analyzed 1 participants 4 participants
0.00 [1]   (NA) 21.67  (13.744)
Gastrointestinal Symptoms: Cycle 38 Number Analyzed 0 participants 4 participants
27.92  (20.520)
Gastrointestinal Symptoms: Cycle 39 Number Analyzed 1 participants 3 participants
6.67 [1]   (NA) 31.11  (19.245)
Gastrointestinal Symptoms: Cycle 40 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 26.67  (17.638)
Gastrointestinal Symptoms: Cycle 41 Number Analyzed 0 participants 3 participants
35.56  (21.430)
Gastrointestinal Symptoms: Cycle 42 Number Analyzed 0 participants 2 participants
33.33  (18.856)
Gastrointestinal Symptoms: Cycle 43 Number Analyzed 0 participants 1 participants
20.00 [1]   (NA)
Gastrointestinal Symptoms:EOT Number Analyzed 33 participants 29 participants
23.23  (18.568) 18.85  (19.766)
Treatment Related Symptoms: Cycle 1 Number Analyzed 19 participants 13 participants
12.57  (14.797) 16.24  (19.038)
Treatment Related Symptoms: Cycle 2 Number Analyzed 56 participants 36 participants
14.48  (11.686) 16.20  (14.141)
Treatment Related Symptoms: Cycle 3 Number Analyzed 49 participants 39 participants
15.42  (12.280) 17.09  (18.574)
Treatment Related Symptoms: Cycle 4 Number Analyzed 45 participants 36 participants
17.53  (15.622) 13.89  (16.074)
Treatment Related Symptoms: Cycle 5 Number Analyzed 45 participants 31 participants
15.06  (11.522) 14.52  (15.361)
Treatment Related Symptoms: Cycle 6 Number Analyzed 41 participants 30 participants
15.45  (13.293) 15.00  (17.577)
Treatment Related Symptoms: Cycle 7 Number Analyzed 37 participants 27 participants
18.77  (16.216) 15.84  (17.207)
Treatment Related Symptoms: Cycle 8 Number Analyzed 35 participants 24 participants
20.48  (19.930) 14.12  (17.870)
Treatment Related Symptoms: Cycle 9 Number Analyzed 32 participants 23 participants
18.23  (15.917) 14.01  (17.558)
Treatment Related Symptoms: Cycle 10 Number Analyzed 33 participants 23 participants
15.99  (15.760) 16.91  (17.446)
Treatment Related Symptoms: Cycle 11 Number Analyzed 35 participants 24 participants
16.83  (16.196) 15.05  (21.453)
Treatment Related Symptoms: Cycle 12 Number Analyzed 34 participants 21 participants
16.01  (18.989) 11.11  (13.494)
Treatment Related Symptoms: Cycle 13 Number Analyzed 32 participants 19 participants
15.45  (12.441) 7.89  (8.942)
Treatment Related Symptoms: Cycle 14 Number Analyzed 29 participants 19 participants
13.60  (12.386) 11.70  (13.968)
Treatment Related Symptoms: Cycle 15 Number Analyzed 28 participants 16 participants
15.48  (12.950) 8.68  (12.664)
Treatment Related Symptoms: Cycle 16 Number Analyzed 25 participants 15 participants
13.78  (13.714) 10.74  (14.467)
Treatment Related Symptoms: Cycle 17 Number Analyzed 21 participants 15 participants
14.81  (15.941) 7.41  (8.572)
Treatment Related Symptoms: Cycle 18 Number Analyzed 16 participants 14 participants
17.71  (16.999) 10.71  (11.828)
Treatment Related Symptoms: Cycle 19 Number Analyzed 10 participants 14 participants
20.00  (17.013) 12.30  (13.287)
Treatment Related Symptoms: Cycle 20 Number Analyzed 10 participants 12 participants
18.33  (17.382) 9.72  (11.392)
Treatment Related Symptoms: Cycle 21 Number Analyzed 11 participants 12 participants
18.18  (18.608) 14.81  (14.279)
Treatment Related Symptoms: Cycle 22 Number Analyzed 10 participants 11 participants
24.44  (22.253) 12.63  (12.691)
Treatment Related Symptoms: Cycle 23 Number Analyzed 10 participants 10 participants
22.22  (23.570) 13.89  (13.671)
Treatment Related Symptoms: Cycle 24 Number Analyzed 9 participants 10 participants
22.84  (24.602) 11.67  (13.969)
Treatment Related Symptoms: Cycle 25 Number Analyzed 8 participants 8 participants
21.53  (21.504) 15.28  (14.164)
Treatment Related Symptoms: Cycle 26 Number Analyzed 7 participants 7 participants
26.19  (21.448) 12.70  (11.437)
Treatment Related Symptoms: Cycle 27 Number Analyzed 6 participants 8 participants
37.96  (16.636) 19.44  (18.306)
Treatment Related Symptoms: Cycle 28 Number Analyzed 5 participants 8 participants
35.56  (21.009) 17.36  (15.555)
Treatment Related Symptoms: Cycle 29 Number Analyzed 4 participants 7 participants
16.67  (4.536) 15.87  (12.184)
Treatment Related Symptoms: Cycle 30 Number Analyzed 3 participants 7 participants
20.37  (3.208) 15.87  (14.138)
Treatment Related Symptoms: Cycle 31 Number Analyzed 3 participants 7 participants
22.22  (11.111) 20.63  (17.484)
Treatment Related Symptoms: Cycle 32 Number Analyzed 3 participants 6 participants
16.67  (5.556) 20.37  (7.590)
Treatment Related Symptoms: Cycle 33 Number Analyzed 3 participants 6 participants
22.22  (11.111) 20.37  (7.590)
Treatment Related Symptoms: Cycle 34 Number Analyzed 3 participants 6 participants
27.78  (9.623) 20.37  (12.989)
Treatment Related Symptoms: Cycle 35 Number Analyzed 2 participants 6 participants
11.11  (15.713) 17.59  (11.340)
Treatment Related Symptoms: Cycle 36 Number Analyzed 1 participants 5 participants
16.67 [1]   (NA) 25.56  (7.454)
Treatment Related Symptoms: Cycle 37 Number Analyzed 1 participants 4 participants
16.67 [1]   (NA) 26.39  (8.333)
Treatment Related Symptoms: Cycle 38 Number Analyzed 0 participants 3 participants
22.22  (11.111)
Treatment Related Symptoms: Cycle 39 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 29.63  (6.415)
Treatment Related Symptoms: Cycle 40 Number Analyzed 1 participants 3 participants
0.00 [1]   (NA) 25.93  (6.415)
Treatment Related Symptoms: Cycle 41 Number Analyzed 0 participants 3 participants
24.07  (8.486)
Treatment Related Symptoms: Cycle 42 Number Analyzed 0 participants 2 participants
27.78  (7.857)
Treatment Related Symptoms: Cycle 43 Number Analyzed 0 participants 1 participants
33.33 [1]   (NA)
Treatment Related Symptoms: EOT Number Analyzed 29 participants 27 participants
24.33  (20.542) 20.78  (24.969)
Social Functioning: Cycle 1 Number Analyzed 61 participants 44 participants
35.34  (22.907) 31.06  (20.132)
Social Functioning: Cycle 2 Number Analyzed 57 participants 41 participants
30.99  (21.490) 29.81  (22.695)
Social Functioning: Cycle 3 Number Analyzed 55 participants 40 participants
29.49  (20.534) 30.00  (25.061)
Social Functioning: Cycle 4 Number Analyzed 50 participants 38 participants
27.00  (19.441) 26.17  (22.331)
Social Functioning: Cycle 5 Number Analyzed 47 participants 33 participants
27.90  (19.087) 24.24  (22.473)
Social Functioning: Cycle 6 Number Analyzed 43 participants 31 participants
25.71  (21.138) 28.32  (23.101)
Social Functioning: Cycle 7 Number Analyzed 39 participants 29 participants
29.06  (20.171) 27.20  (26.157)
Social Functioning: Cycle 8 Number Analyzed 37 participants 25 participants
30.63  (20.015) 27.11  (20.051)
Social Functioning: Cycle 9 Number Analyzed 35 participants 26 participants
29.84  (27.715) 23.08  (19.607)
Social Functioning: Cycle 10 Number Analyzed 35 participants 23 participants
28.89  (22.579) 24.64  (24.835)
Social Functioning: Cycle 11 Number Analyzed 35 participants 24 participants
29.21  (21.573) 24.07  (22.383)
Social Functioning: Cycle 12 Number Analyzed 35 participants 22 participants
28.25  (24.454) 23.74  (22.562)
Social Functioning: Cycle 13 Number Analyzed 34 participants 21 participants
24.84  (23.380) 23.81  (23.382)
Social Functioning: Cycle 14 Number Analyzed 31 participants 19 participants
27.96  (20.056) 25.73  (24.018)
Social Functioning: Cycle 15 Number Analyzed 30 participants 17 participants
28.52  (20.149) 28.76  (28.070)
Social Functioning: Cycle 16 Number Analyzed 27 participants 16 participants
27.16  (20.286) 27.78  (23.307)
Social Functioning: Cycle 17 Number Analyzed 22 participants 15 participants
28.79  (21.320) 23.70  (22.564)
Social Functioning: Cycle 18 Number Analyzed 17 participants 14 participants
29.41  (26.040) 26.98  (21.666)
Social Functioning: Cycle 19 Number Analyzed 12 participants 14 participants
29.63  (25.219) 28.57  (22.943)
Social Functioning: Cycle 20 Number Analyzed 11 participants 13 participants
31.82  (28.119) 29.06  (28.160)
Social Functioning: Cycle 21 Number Analyzed 11 participants 12 participants
35.35  (30.151) 24.07  (23.130)
Social Functioning: Cycle 22 Number Analyzed 11 participants 11 participants
31.31  (28.029) 27.27  (24.527)
Social Functioning: Cycle 23 Number Analyzed 11 participants 10 participants
30.30  (28.149) 26.67  (27.317)
Social Functioning: Cycle 24 Number Analyzed 10 participants 10 participants
38.89  (28.328) 24.44  (24.456)
Social Functioning: Cycle 25 Number Analyzed 10 participants 8 participants
35.56  (27.116) 31.94  (26.184)
Social Functioning: Cycle 26 Number Analyzed 7 participants 7 participants
46.03  (28.276) 22.22  (11.111)
Social Functioning: Cycle 27 Number Analyzed 6 participants 8 participants
51.85  (28.689) 33.33  (28.483)
Social Functioning: Cycle 28 Number Analyzed 7 participants 8 participants
46.03  (33.597) 31.94  (29.360)
Social Functioning: Cycle 29 Number Analyzed 6 participants 7 participants
35.19  (25.740) 28.57  (27.857)
Social Functioning: Cycle 30 Number Analyzed 5 participants 7 participants
35.56  (26.527) 30.16  (29.893)
Social Functioning: Cycle 31 Number Analyzed 3 participants 7 participants
44.44  (22.222) 30.16  (29.197)
Social Functioning: Cycle 32 Number Analyzed 3 participants 6 participants
33.33  (11.111) 31.48  (30.965)
Social Functioning: Cycle 33 Number Analyzed 3 participants 6 participants
40.74  (23.130) 40.74  (31.164)
Social Functioning: Cycle 34 Number Analyzed 3 participants 6 participants
44.44  (22.222) 35.19  (29.327)
Social Functioning: Cycle 35 Number Analyzed 2 participants 6 participants
38.89  (23.570) 33.33  (24.343)
Social Functioning: Cycle 36 Number Analyzed 1 participants 5 participants
22.22 [1]   (NA) 31.11  (27.666)
Social Functioning: Cycle 37 Number Analyzed 1 participants 4 participants
22.22 [1]   (NA) 30.56  (39.933)
Social Functioning: Cycle 38 Number Analyzed 0 participants 4 participants
41.67  (41.944)
Social Functioning: Cycle 39 Number Analyzed 1 participants 3 participants
33.33 [1]   (NA) 51.85  (44.905)
Social Functioning: Cycle 40 Number Analyzed 1 participants 3 participants
11.11 [1]   (NA) 42.59  (36.991)
Social Functioning: Cycle 41 Number Analyzed 0 participants 3 participants
44.44  (40.062)
Social Functioning: Cycle 42 Number Analyzed 0 participants 2 participants
38.89  (39.284)
Social Functioning: Cycle 43 Number Analyzed 0 participants 1 participants
11.11 [1]   (NA)
Social Functioning: EOT Number Analyzed 33 participants 29 participants
39.73  (25.914) 41.38  (26.874)
Disease Related Worries: Cycle 1 Number Analyzed 61 participants 43 participants
49.27  (26.381) 42.89  (23.108)
Disease Related Worries: Cycle 2 Number Analyzed 57 participants 41 participants
38.01  (24.550) 36.04  (24.942)
Disease Related Worries: Cycle 3 Number Analyzed 55 participants 40 participants
36.46  (23.074) 34.58  (23.853)
Disease Related Worries: Cycle 4 Number Analyzed 50 participants 38 participants
31.89  (22.075) 33.19  (23.904)
Disease Related Worries: Cycle 5 Number Analyzed 47 participants 33 participants
37.12  (25.619) 30.64  (22.742)
Disease Related Worries: Cycle 6 Number Analyzed 43 participants 31 participants
36.43  (25.148) 34.05  (25.000)
Disease Related Worries: Cycle 7 Number Analyzed 39 participants 29 participants
39.32  (24.825) 32.18  (26.618)
Disease Related Worries: Cycle 8 Number Analyzed 37 participants 25 participants
38.29  (25.653) 32.00  (22.753)
Disease Related Worries: Cycle 9 Number Analyzed 35 participants 26 participants
35.71  (31.116) 32.05  (22.072)
Disease Related Worries: Cycle 10 Number Analyzed 35 participants 23 participants
37.30  (26.458) 28.02  (26.563)
Disease Related Worries: Cycle 11 Number Analyzed 35 participants 24 participants
35.87  (25.292) 27.78  (22.700)
Disease Related Worries: Cycle 12 Number Analyzed 35 participants 22 participants
35.56  (28.621) 29.29  (25.325)
Disease Related Worries: Cycle 13 Number Analyzed 34 participants 21 participants
34.64  (27.046) 30.16  (24.881)
Disease Related Worries: Cycle 14 Number Analyzed 31 participants 19 participants
32.97  (22.312) 31.87  (22.055)
Disease Related Worries: Cycle 15 Number Analyzed 30 participants 17 participants
34.44  (25.160) 33.66  (27.250)
Disease Related Worries: Cycle 16 Number Analyzed 27 participants 16 participants
34.16  (25.022) 37.85  (23.589)
Disease Related Worries: Cycle 17 Number Analyzed 22 participants 15 participants
29.80  (22.059) 34.07  (27.043)
Disease Related Worries: Cycle 18 Number Analyzed 17 participants 14 participants
30.07  (28.805) 32.14  (27.232)
Disease Related Worries: Cycle 19 Number Analyzed 12 participants 14 participants
37.50  (29.504) 31.75  (28.862)
Disease Related Worries: Cycle 20 Number Analyzed 11 participants 13 participants
40.40  (32.687) 29.91  (31.877)
Disease Related Worries: Cycle 21 Number Analyzed 11 participants 12 participants
39.90  (30.512) 27.78  (30.887)
Disease Related Worries: Cycle 22 Number Analyzed 11 participants 11 participants
33.33  (31.032) 30.30  (34.816)
Disease Related Worries: Cycle 23 Number Analyzed 11 participants 10 participants
36.36  (35.168) 26.11  (29.403)
Disease Related Worries: Cycle 24 Number Analyzed 10 participants 10 participants
41.11  (32.309) 27.78  (28.328)
Disease Related Worries: Cycle 25 Number Analyzed 10 participants 8 participants
38.33  (32.547) 38.89  (31.983)
Disease Related Worries: Cycle 26 Number Analyzed 7 participants 7 participants
42.86  (33.597) 31.75  (33.597)
Disease Related Worries: Cycle 27 Number Analyzed 6 participants 8 participants
52.78  (40.023) 34.72  (28.133)
Disease Related Worries: Cycle 28 Number Analyzed 7 participants 8 participants
50.79  (38.946) 40.28  (39.368)
Disease Related Worries: Cycle 29 Number Analyzed 6 participants 7 participants
37.96  (35.210) 38.10  (35.635)
Disease Related Worries: Cycle 30 Number Analyzed </